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ABSTRACT 
Friedreich Ataxia (FRDA) is an autosomal recessive degenerative disorder.  It is caused 
by an abnormal expansion of GAA trinucleotide repeats in the first intron of the gene 
encoding frataxin.  Since rates of cell division have been linked to oxidative stress, we 
have examined several parameters of oxidative stress in a FRDA primary fibroblast cell 
line that had a dramatically different growth rate.  In the FRDA fibroblasts, the high 
level of reactive oxygen species (ROS) indicated elevated oxidative stress.  The elevated 
glutathione peroxidase (Gpx) activity in the ROS defense system may represent an 
adaptive response to the high oxidative stress.   The increased mitochondrial membrane 
potential (MMP) likely contributed to increased oxidant production, which could be 
contributed by elevated ROS.  This increased oxidant production might be responsible 
for increased rate of progression through the cell cycle. 
Furthermore, the elevated oxidative stress is also associated with progressive neural 
pathology of FRDA.  In FRDA, pathology is first seen in the dorsal root ganglia and the 
dorsal columns of the spinal cord.  Due to the abnormal metal distribution seen in the 
FRDA spinal cord and medulla, we hypothesized that metal binding proteins were 
abnormally distributed in FRDA.  In our FRDA samples, we observed the well 
established histopathology of FRDA and examined the distribution of some metal binding 
proteins (frataxin, ferritin and metallothionein) through immunohistochemistry.  Our 
results showed demyelination and loss of axons in the degeneration areas of the two FRDA 
cases.  In addition, we found that the metal binding proteins were abnormally distributed 
in the FRDA spinal cord and the medulla.  The abnormal distributions of the metal 
binding proteins were characterized by low expressions of iron binding proteins, especially 
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frataxin and cytosolic ferritin, and undetectable expression of the copper and zinc binding 
protein, metallothionein. 
In summary, the rapid cell growth is a feature of FRDA fibroblast cell lines. We also 
tested Gpx activity, measured oxidant levels and determined the MMP in a FRDA 
primary fibroblast cell line that had a dramatically fast growth rate.  The FRDA 
histopathology studies showed the metal binding proteins including frataxin, ferritin and 
metallothionein were abnormally distributed in the spinal cord and the medulla. 
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Chapter 1 Cell proliferation-associated oxidative stress in FRDA 
fibroblasts 
1.1 Introduction  
1.1.1 Friedreich Ataxia (FRDA)  
Friedreich Ataxia is an autosomal recessive degenerative disorder (Delatycki et al., 2000). 
It is the most common hereditary ataxia with an incidence of 1 in 50 000 individuals of 
Western European, North African, Indian and Middle Eastern origin.  The founder 
effect has been established by testing individuals from different families from these 
regions (Labuda et al., 2000).  All of the tested patients showed positive GAA repeat 
expansions.  But this result was seen in neither the chromosome without FRDA gene in 
the same families nor ataxic individuals from other regions of the world.  This particular 
geographic distribution is caused by the inheritance of a genetic defect involving a 
trinucleotide repeat expansion (Delatycki et al., 2000; Pandolfo, 2008).  Most (about 
96%) of FRDA patients have an abnormal expansion of GAA trinucleotide repeats in the 
first intron of the gene encoding frataxin.  The rest, approximately 2-5%, of patients 
have a mixture of frataxin point mutations and GAA expansions (Campuzano et al., 
1996).  The normal first intron of the frataxin gene has approximately 38 GAA repeats, 
while the number could rise to around 600 to 900 for most disease-associated frataxin 
genes (Pandolfo, 2008).  The abnormal GAA repeat affects DNA transcription that 
therefore decreases frataxin protein expression.   
Frataxin, a 210 amino acid protein, is highly conserved in eukaryotes as well as many 
prokaryotes (Pandolfo, 2008).  Although the exact functions of frataxin are still 
controversial, generally frataxin is involved in iron homeostasis including biosynthesis of 
heme and iron-sulfur (Fe-S) cluster assembly.  Frataxin works directly on the 
biosynthesis of heme, delivering ferrous iron to ferrochelatase, the enzyme that catalyzes 
the final step in the biosynthesis of heme (Bencze et al., 2006).  Based on the yeast 
studies, mitochondrial iron shortage to heme and heme biosynthesis defects occur when 
there is a lack of frataxin (Becker et al., 2002).  These findings indicate that frataxin 
deficiency reduced iron going to heme biosynthesis and resulted in the heme biosynthesis 
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deficiency.  Heme biosynthesis would be also affected by other factors, for example, the 
activity of Fe-S enzyme (ferrochelatase) but in this experiment, other factors were not 
tested.  In FRDA lymphoblasts, the defects of heme synthesis came after the defects of 
Fe-S cluster assembly (Napoli et al., 2007).  Although the decrease of ferrochelatase 
activity was not observed in frataxin knock out oligodendroglioma, there was a decreased 
activity of ferredoxin, which is the only other Fe-S enzyme that is known to be involved 
in the heme synthesis (Napoli et al., 2007).   
Iron sulphur (Fe-S) clusters are prosthetic residues of various groups of proteins acting in 
electron transport, enzyme catalysis, and regulation of gene expression.  Fe-S 
cluster-containing proteins can be found in electron transport chain (complex I, II and III), 
energy metabolism (aconitase), and DNA repair (DNA glycosylase) (Bencze et al., 2006).  
Frataxin passes ferrous iron to an intracellular scaffold protein U (IscU), so that the Fe-S 
cluster is formed (Pandolfo, 2008).  In frataxin-deleted mouse tissues, the level of Fe-S 
scaffold protein IscU decreased, which contributed to the deficit of Fe-S 
cluster-containing proteins (Martelli et al., 2007).  The effect of frataxin deficiency on 
Fe-S cluster-containing proteins in the FRDA yeast model showed the same results as in 
the mammal.  Most Fe-S cluster-containing proteins were decreased upon frataxin 
depletion (Pandolfo, 2008; Martelli et al., 2007) 
Besides working as an iron donor for the biosynthesis of heme and Fe-S cluster assembly, 
other functions of frataxin have been found.  Frataxin can also function as an 
iron-binding and iron storage protein (Adamec et al., 2000).  The chemical form of iron 
stored in both yeast and human frataxin polymers is ferrihydrite (Nichol et al., 2003).  
The oxidation state of iron in ferrihydrite is ferric iron, which is the oxidized form within 
cells.  The crystal structure of iron-loaded frataxin suggested its functions include metal 
delivery and detoxification (Karlberg, 2006). 
1.1.2 Reactive oxygen species  
1.1.2.1 Introduction to reactive oxygen species 
Reactive oxygen species (ROS) are the by-products generated during cell metabolism.  
The major source of ROS is mitochondria.  About 3% of oxygen is incompletely used 
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under normal physiological conditions within mitochondria and subsequently oxygen 
forms superoxide anion (O2
.-
) (Fridovich, 1986).  The initial ROS O2
.-
 can be rapidly 
converted into H2O2 catalyzed by superoxide dismutase (SOD).  H2O2 is capable of 
efficiently interacting with ferrous iron in the Fenton reaction (Fenton, 1894).   
Fe2+ + H2O2  Fe3+ + OH
.
 + OH- 
Hydroxyl radical (OH
.
) is extremely reactive and harmful to many cellular contents.  
Hydroxyl radical can damage proteins, nucleic acids and lipids through oxidation.  
Besides iron, other transition metals like copper, manganese and cobalt are able to carry 
out the reaction.  For example, copper can also perform this reaction with even better 
efficiency however free copper can barely be detected, while intracellular free iron can be 
detected in low micromolar concentrations (Barbouti et al., 2001). 
1.1.2.2 Iron and Reactive oxygen species in Friedreich Ataxia 
Free iron is so dangerous that it is extremely controlled by cells, however abnormal iron 
regulation has been indicated in FRDA (Pandolfo, 2008).  The accumulation of iron has 
been found within mitochondria in FRDA patients as well as in frataxin knockout yeast 
(yfh1p, frataxin homolog) (Waldvogel et al., 1999; Babcock et al., 1997).  The 
elevated mitochondrial iron was measured by using atomic absorption spectroscopy, a 
technique to determine the concentration of a particular metal element (Babcock et al., 
1997). Although the level of iron is elevated in FRDA mitochondria, the chemical form of 
iron has only recently been identified (Popescu et al., 2007).  Most iron within FRDA 
fibroblast mitochondria exists in a safe form of ferrihydrite stored mostly in 
mitochondrial ferritin, with only a small amount in frataxin (Popescu et al., 2007).  
Some bio-markers of oxidative stress have been examined in FRDA patients such as 
increased plasma levels of malondialdehyde (lipid peroxidation product) (Emond et al., 
2000), and increased levels of urinary 8-hydroxy-2’-deoxyguanosine (8OH2’dG, 
oxidative DNA damage marker) (Schulz et al., 2000).  Since oxidative stress has been 
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examined in FRDA, antioxidants were used to fight against oxidative stress as one of the 
therapies.  The antioxidants such as coenzyme Q10 as well as its analog idebenone and 
Vitamin E have been developed as drug therapies to improve the symptoms of FRDA 
(Lodi et al., 2001) (Cooper & Schapira, 2007).  However the antioxidant therapy does 
not always work on the FRDA.  No positive effects were observed when a Mn-SOD 
mimetic (MnTBAP), functioning as an antioxidant enzyme, was examined as the 
treatment of a conditional frataxin knockout mouse (Seznec et al., 2005).  Iron 
accumulation within mitochondria was thought to be the main source of oxidative stress 
in FRDA, however, the treatment with this antioxidant suggests that the mitochondrial 
iron accumulation may not contribute to cellular oxidative stress in FRDA (Seznec et al., 
2005).   
Mitochondrial dysfunction has been shown as a consequence of frataxin deficiency.  In 
skeletal muscle and heart of FRDA patients, there is a reduced rate of adenosine 
triphosphate (ATP) synthesis (Lodi et al., 1999).  Mitochondrial membrane potential 
(MMP) is viewed as an important marker revealing mitochondrial function (Zhang et al., 
2006).  A low MMP has been suggested in a frataxin mutant yeast model (Zhang et al., 
2006).  Furthermore, MMP was lower than the control in FRDA lymphoblasts (Tan et 
al., 2001).  However, this low MMP can be rescued to control levels through 
transfecting frataxin to FRDA lymophoblasts.  This suggested that the mitochondrial 
enzymes that support MMP might be deficient.  
1.1.2.3 Reactive oxygen species effects on cell cycle progression 
ROS can damage lipids, proteins, carbohydrates and nucleic acids, and subsequently lead 
to cell growth arrest, apoptosis or necrosis (Boonstra & Post, 2004; Burdon, 1995; 
Martindale & Holbrook, 2002).  ROS plays an important role in cell cycle proliferation 
through activating cellular signal transduction pathways (Burdon, 1995; Martindale & 
Holbrook, 2002); (Boonstra & Post, 2004).  This activation can result in the arrest of 
cell proliferation in the G1 phase of the cell cycle, while possibly other phases of the cell 
cycle might also be affected or stopped, depending upon the localization of ROS.  For 
example, ROS-induced DNA damage could increase transcription factor-p53 activity, and 
subsequently up-regulate the level of p21, a regulator of cell cycle progression.  In this 
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case, cell proliferation was stopped in all phases of the cell cycle and the DNA repair was 
started (Boonstra & Post, 2004).  
However, some authors have pointed out that low levels of ROS, especially with an 
endogenous origin, can increase cell proliferation (Burdon, 1995; Martindale & Holbrook, 
2002).  In other words, low levels of ROS are required for cell proliferation (Boonstra & 
Post, 2004; Na et al., 2008).  This might indicate that the ROS effect on cell cycle 
progression is dose dependent.  In addition, the origin of ROS generation in the cell may 
also affect cell cycle progression.   
1.1.3 Antioxidants and antioxidant enzymes 
Mitochondria have a multi-level defense system that decreases ROS production or 
removes generated ROS.  This system involves antioxidants, such as glutathione (GSH) 
that decreases ROS production, enzymes that directly react with ROS, and non-enzymatic 
antioxidants (e.g.vitamin E) that remove ROS (Czarna & Jarmuszkiewicz, 2006).  The 
antioxidant enzymes are involved in ROS defense system for example, SOD that is found 
in both the cytosol and mitochondria, glutathione peroxidase (Gpx) that is found in both 
compartments and catalase that is found in peroxisomes (Calabrese et al., 2005). 
As shown in Fig 1.1, superoxide is generated from oxygen mainly through NADPH 
oxidase and mitochondrial electron transport chain.  However, in the ROS defense 
system, superoxide can be converted into hydrogen peroxide catalyzed by SOD, and 
hydrogen peroxide is subsequently converted to water by either catalase or by Gpx using 
GSH as an electron donor. In the presence of glutathione reductase, oxidized form of 
GSH (GSSG) can be converted to GSH (Roman, 2008).  
1.1.3.1 Superoxide dismutases 
The SOD, a ubiquitous enzyme, catalyzes the dismutation of superoxide anion into 
oxygen and hydrogen peroxide.  There are three types of superoxide dismutase present 
in the human body.  They are distinguished based on their different localizations.   
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Fig 1.1 Generation and scavenging of superoxide and hydrogen peroxide  
Superoxide is mainly generated through NADPH oxidase and mitochondrial electron 
transport chain.  However, in the ROS defense system, superoxide can be converted into 
hydrogen peroxide catalyzed by SOD, and hydrogen peroxide is subsequently converted 
to water by catalase or by Gpx using GSH as an electron donor. 
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SOD1 (Cu, Zn-SOD) is located in the cytoplasm, SOD2 (Mn-SOD) is in the 
mitochondria and SOD3 (Cu, Zn-SOD) localized extracellularly (Culotta et al., 2006).  
This is an important antioxidant defense when cells first encounter oxidative stress.  
Total SOD activities were up-regulated in normal human fibroblasts in response to 
oxidative stress; while this defense was not induced in FRDA fibroblasts 
(Chantrel-Groussard et al., 2001).  This finding indicated the impaired antioxidant 
defense in FRDA patients, but the SOD defense exhibited differently in yeast.  In the 
frataxin knockout yeast (yfh1p) (frataxin homolog), Cu,Zn-SOD1 and Mn-SOD were 
reported to be up-regulated (Irazusta et al., 2006; Wilson, 2006) as a response to frataxin 
deficiency induced oxidative stress. 
1.1.3.2 Glutathione peroxidase 
Gpx, a selenoprotein, catalyzes the reduction of harmful organic peroxides (such as 
hydrogen peroxide as well as phospholipid hydroperoxides) to water and/or 
corresponding alcohols by using GSH as an electron donor.  In frataxin deficient FRDA 
yeast cells, Gpx activity was higher in cytosol as well as mitochondria than in normal 
controls (Auchere et al., 2008).  This may indicate the severe status of oxidative stress 
in FRDA yeast cells.  The average of Gpx activity coming from four FRDA patients in 
the whole blood was about 34% lower than normal (Fryer, 2002).  
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1.2 Research Objectives and Hypotheses 
Based on pilot studies, the hypotheses are: 
Hypothesis 1: FRDA fibroblasts grow more rapidly than control fibroblasts. 
Hypothesis 2: The rapid growing FRDA fibroblast cells are associated with increased 
oxidative stress. 
Research Objectives:  
1. To determine the growth rate of primary fibroblasts from FRDA patients and  
matched control fibroblasts, 
2. To determine the activity of the antioxidant enzyme glutathione peroxidase in the 
rapid growing FRDA fibroblasts and normal control fibroblast cell lines, 
3. To determine the level of reactive oxygen species, which is an indicator of the level 
of oxidative stress in the rapid growing FRDA and normal control fibroblast cell 
lines, 
4. To determine mitochondrial membrane potential which indicates mitochondrial 
function as well as the intensity of oxidant production in the rapid growing FRDA 
and the normal control cell line. 
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1.3 Methods 
1.3.1 Cell culture 
Primary fibroblast cell lines from clinically identified FRDA patients (GM04078 and 
GM03816) (see Table 1) were purchased from Coriell Cell Repositories (Camden, New 
Jersey).  The control primary fibroblast cell line (MCH070), used for long-term study, 
was purchased from The Canadian Repository for Mutant Human Cell Strains (Montreal, 
Quebec) and control primary fibroblast cell lines  (GM08402 and GM08400), used for 
short-term study, were purchased from Coriell Cell Repositories.  Cells were grown at 
37 °C in an incubator (5% CO2) in Minimum Essential Medium (GIBICO Laboratories, 
Grand Island, NY) supplemented with 10% Fetal Bovine Serum (FBS) (Hyclone, Logan, 
UT) as well as antibiotics and antimycotics (100 units/mL, Sigma, St Louis, MO) (see 
appendix).   
1.3.2 Growth rate measurement 
The cell lines involved in the cell growth rate experiment were FRDA primary fibroblasts: 
GM04078 and GM 03816. Unaffected control primary fibroblasts were GM08402 and 
GM08400.  All cells were initially planted and grown in 60mm dishes with 12,000 cells 
per dish for each cell line.  Cell counts were performed on day 3, 5 and 7.  Three 
individual dishes were counted for each cell line each time.  400μL of cell suspension 
was stained with 100μL 0.3% Nigrosin (Sigma, St Louis, MO) for 3 minutes.  A 
hemacytometer was used to count the numbers of cells.  Only cells that excluded 
nigrosin were counted as viable cells from each square on both sides of the 
hemacytometer and the results were averaged.  The unpaired T-test was used to 
determine whether the observed difference between the means was statistically 
significant.  
Both FRDA and control (CTRL) cell lines used in the experiment are listed above with 
sex of the donor, identification code and the number of GAA repeats in each allele of the 
frataxin gene.  There are fewer than 66 GAA repeats in the normal frataxin gene, 
however very severe cases of FRDA can have 600 to 900 (Pandolfo, 2008). 
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Table 1.  List of primary fibroblast cell lines used in the experiment. 
 Sex Coriell/McGill ID GAA repeats  
per allele 
M GM04078 420/541  
FRDA F GM03816 330/380 
M MCH070 <66/66 
M GM08402 < 66/66 
 
CTRL 
F GM08400 < 66/66 
 
1.3.3 Glutathione peroxidase (Gpx) activity assay  
FRDA and control primary fibroblast cells were plated with the same number of cells and 
grown to 80% confluency in a 6-well plate.  The Gpx activity assay was performed 
using a kit from Cayman Chemical (Catalog #: 703102, Ann Arbor, MI) according to the 
manufacturer’s instructions.  Glutathione (GSH) can be oxidized by hydroperoxide in 
the presence of Gpx.  The oxidized form of GSH can be recycled to its reduced form by 
NADPH in the presence of glutathione reductase.  Since NADPH has an absorbance at 
340nm, the Gpx activity was measured indirectly through the decrease in absorbance of 
NADPH.   
1.3.3.1 Preparation of cell lysates  
Cells were collected from one well of a 6-well plate by adding 700μL of Gpx kit Assay 
buffer (50mM Tris-HCl plus 5mM EDTA, pH 7.6).  The cell pellet was collected by 
centrifuging at 4 °C, 2000g for 10 minutes.  The cell pellet was re-suspended in 100μL 
of Assay buffer plus 1mM dithiothreitol (DTT).  The suspension was kept on ice and 
sonicated 3 times for 10 seconds each time.  Enzymes were isolated by centrifugation at 
4 °C, 10,000g for 15 minutes.  The supernatant was removed and stored at -80 °C.  The 
Bradford protein assay (according to the Instruction Manual of “Quick start Bradford 
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protein assay” (BioRad, USA) was conducted on the day when the enzyme activity was 
performed.  
1.3.3.2 Gpx activity 
All the samples, including the Gpx control, were diluted to the protein concentration of 
the sample with the lowest protein content.  The assay was performed in a 96-well plate 
and the total volume for each well was 190μL.  First, substrate complexes including 
NADPH, GSH and glutathione reductase were added as 50μL per well.  Then, 20μL of 
diluted sample was added.  Last, 100μL of Assay buffer was added.  A well with 
120μL Assay buffer only was used as a negative control.  In order to initiate the reaction, 
20μL of cumene hydroperoxide was added to all of the wells being tested.  The well 
plate was shaken for 5 seconds on the plate reader.  The absorption value was collected 
at 340nm, every 30 seconds for 5 minutes.  The readings between time1 and time 2 were 
expected to be within a linear range.  The Gpx activity was calculated by the following 
formulas.  The unpaired T-test was used to determine whether the observed difference 
between the means was statistically significant. 
A340 (time 2) - A340 (time 1) ∆ A340/min.   = 
Time 2 - Time 1 
 Gpx activity 
  (nmol/min/µg) 
 
 
∆A340/min.
× ×
 
Note: 0.0037 μM-1 is NADPH extinction coefficient. 
0.0037μM
-1
0.19 mL 
0.02 mL 
Dilution factor = 
1.3.4 Reactive oxygen species assay  
The reactive oxygen species assay was performed using Mitotracker Red CM-H2XRos 
(Molecular Probes, Eugene, OR).  This particular mitochondrial-targeting dye will not 
fluoresce until oxidized by intracellular reactive oxygen species (ROS) and sequestered 
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in mitochondria through binding the reactive thiol of its chloromethyl moiety (Poot et al., 
1996).  Both control and FRDA fibroblast cells, with the same or similar passage 
number, were plated.  Control and FRDA primary fibroblast cells were plated with the 
same number of cells and grown to 70% of confluence on 22×22 mm cover slips in a 
6-well plate.  Cells growing on cover slips were stained with 50 nM Mitotracker Red 
CM-H2XRos in a 37°C incubator for 30 minutes.  Extra dye and dye solution were 
removed by washing with pre-warmed medium for 10 minutes.  Cells were washed 
again with 0.03M PBS once prior to fixation.  3.7% formaldehyde was used to fix cells 
at 37 °C for 15 minutes.  Then cells were washed with 0.03M PBS twice, 15 minutes 
each.  Nuclei were stained with 0.5μg/ml Hoechst (Sigma, St Louis, MO) at room 
temperature for 15 minutes.  After washing with 0.03M PBS twice, 15 minutes each, 
photographs were taken by an Olympus IX70 microscope equipped with 40× LCPlan FI.  
0.6 objective lens. The amount of red in the micrographs was quantified using ImageJ 
Color Histogram. 
1.3.5 Mitochondrial membrane potential (MMP) 
1.3.5.1 Preparation and staining of cells 
Both control and FRDA fibroblast cells, with the same or similar passage number, were 
plated as previously described.  Cells were collected after 24 hours through 
trypsinization and centrifugation at 1000g for 10 minutes.  The pellet was re-suspended 
in 5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethlbenzimidazolcarbocyanine iodide (JC-1) 
(Molecular Probes, Eugene, OR) with the final concentration of 1μg/μL in the buffer of 
MEM plus 10% FBS.  Cells were stained in a 37°C incubator for 20 minutes.  Extra 
dye and dye solution were removed by centrifuging at 1000g for 10 minutes.  The cell 
pellet was re-suspended in 0.03M PBS. 
1.3.5.2 Mitochondrial membrane potential measurement 
The mitochondrial membrane potential was tested by using a fluorochrome-JC-1.  JC-1 
can pass through the plasma membrane of cells as monomers.  The uptake of JC-1 from 
cytoplasm into mitochondria is driven by the mitochondrial membrane potential.  The 
more JC-1 taken up into mitochondria, the more JC-1 aggregates are formed.  The two 
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different states of JC-1, monomers and aggregates, have different excitation and emission 
spectra.  The mitochondrial membrane potential is calculated by the ratio of aggregates 
to monomers.  The unpaired T-test was used to determine whether the observed 
difference between the means was statistically significant.  Flow cytometry was done at 
the Saskatoon Cancer Center, University of Saskatchewan on a fee-for-service basis.  
The flow cytometer was an EPICS XL Flow Cytometer from Beckman-Coulter. 
1.4 Results 
1.4.1 Some FRDA fibroblasts grow more quickly than control fibroblasts 
Fibroblasts were cultured as described in section 1.3.1.  The rate of growth was 
determined over a period of 8 weeks (Fig. 1.2A).  Fig. 1.2 shows that the growth rate of 
FRDA fibroblasts from a male patient (GM04078) was greater than that of control 
fibroblasts (MCH070).  We found that the rate of growth did not decline dramatically 
over time.   
Therefore we conducted a more detailed growth study with 3 replicates using both male 
and female cell lines for 7 days (Fig. 1.2B-C).  Figure 1.2B shows that after 7 days there 
was a statistically significant difference in the number of FRDA male fibroblasts which 
had increased 40 fold while the male control increased only 7 fold (p< 0.01).    The 
female FRDA increased 7 fold in 7 days and the female control increased 4 fold. There 
was a statistical difference of cell number between the FRDA and the control on the date 
of 7 (p<0.05) (Fig. 1.2C).  The growth rate was roughly linear for all cell lines over 7 
days and no decline in growth was seen.  Note that the X and Y axes of panels A, B and 
C have different ranges. 
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Fig. 1.2 FRDA primary fibroblast cell lines grow faster than control fibroblasts.  
(Figure legend continues to the next page) 
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A. Long-term growth curve.  At time 0, 6x104 FRDA or control cells were plated and 
then cultured under identical conditions for 3 weeks and 7 weeks respectively.  FRDA 
male (squares), control male (triangle).  The experiment was conducted only once. 
B. Short-term growth curve.  At time 0, 1.2x104 male FRDA or control cells were plated 
and then cultured under identical conditions for 7 days.  FRDA (square), control 
(triangle).  After 7 days there was a statistical difference of growth rate between FRDA 
and control cell lines (p<0.01).  The error bars present the value of Standard Error of the 
Mean (SEM) of three independent replicates.  
C. Short-term growth curve.  At time 0, 1.2 x104 female FRDA or control cells were 
plated and then cultured under identical conditions for 7 days.  FRDA (square), control 
(triangle).  At the date of 7, there was a statistical difference between the growth of 
FRDA and control cells (p<0.05).    Note that both the X and Y axes of panels A, B 
and C have different ranges.  The error bars present the value of Standard Error of the 
Mean (SEM) of three independent replicates.  
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Since rates of cell division have been linked to oxidative stress (see Introduction section 
1.1.2), we chose to examine several parameters of oxidative stress in the male cells that 
had a dramatically different growth rate. 
1.4.2 Glutathione peroxidase assay: 
GSH functions as an important antioxidant enzyme to protect cells from oxidative 
damage.  Gpx is involved in the reaction of GSH oxidization by converting hydrogen 
peroxide to water.  GSH activity is often increased when a cell is under oxidative stress 
(see Introduction section 1.1.3).  Therefore Gpx is an important measure of oxidative 
stress.  
We measured Gpx activity as described in section 1.3.3.  Three replicates were 
measured for each independent experiment and 5 experiments were conducted in total.  
The Gpx activity was determined for each experiment and normalized to the control 
value.   
The 5 independent experiments were then averaged.  The average of Gpx activity in 
male control fibroblasts was 0.372 nmol/min/µg, and 0.544 nmol/min/µg for the male 
FRDA.  Therefore, the Gpx activity in the male FRDA cells was 1.466 ± 0.131 times or 
about 47% higher than in control cells (t-test showed p<0.01).  There was a statistically 
significant difference in Gpx activity between control and FRDA primary fibroblast cells.  
1.4.3 Reactive oxygen species 
Our first step was to test the level of oxidative stress in the primary human male 
fibroblast cells using the well established Mitotracker dye (see section 1.3.4).  This 
particular mitochondrial-targeting dye will not fluoresce until oxidized by intracellular 
reactive oxygen species (ROS) and sequestered in mitochondria through binding reactive 
thiol of its chloromethyl moiety.  In more than 5 independent experiments, visual 
inspection of many fields of view showed that more Mitotracker was oxidized and 
targeted to mitochondria in FRDA than control fibroblasts.  The amount of red in the 
micrographs quantified by ImageJ Color Histogram showed that the FRDA cells had  
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Fig. 1.3 Mitotracker indicates that ROS are higher in FRDA mitochondria than in control.  
FRDA cells had about 3 times more Mitotracker dye (red) than did controls by using 
ImageJ Color Histogram for analysis.  More dye extends into the cell processes in 
FRDA.  
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about 3 times more red color than did controls.  Fig. 1.3 is representative of what was 
seen.  In the control fibroblasts, labelled mitochondria were mostly around the nucleus 
whereas in the FRDA, the labelled mitochondria were also seen throughout the cellular 
processes (see Discussion section 1.5.2). 
Since FRDA show signs of cellular oxidative stress we chose to examine a sensitive 
parameter of oxidant production: the mitochondrial membrane potential. 
1.4.4 Mitochondrial membrane potential assay 
Mitochondrial membrane potential (MMP) is an important parameter of mitochondrial 
function used as an indicator of oxidant production.  We measured MMP using the well 
established JC-1 assay (see section 1.3.5).  Three replicates were measured for each 
independent experiment and 4 experiments were conducted in total.  The average MMP 
was determined for each experiment and normalized to the control value.  Then the 4 
independent experiments were averaged.  The MMP of FRDA fibroblast cells was 1.245 
± 0.036 times or about 25% higher than in control cells (t-test showed p<0.001).  
Therefore there was a significant difference of mitochondrial membrane potential 
between control and FRDA primary fibroblast cells.  
1.5 Discussion 
1.5.1 FRDA fibroblasts grow more quickly than control fibroblasts 
FRDA is genetically caused by the abnormal long GAA repeats of the first intron of the 
frataxin gene.  As shown in table 1, the numbers of GAA expansion in the two alleles 
for the male patient (Cell line GM04078) are 420 and 541 and for the female patient (Cell 
line GM03816) are 330 and 380.  The number of normal GAA repeats of frataxin gene 
is up to 66, however very severe cases of FRDA can have 600 to 900 (Pandolfo, 2008).   
The patient cells used in this study are in the mid-range of FRDA repeat lengths.  It has 
been reported that the length of GAA repeat inversely correlates with the age of onset 
(Delatycki et al., 2000).  The longer the GAA repeat, the less amount of residual 
frataxin, the earlier the age of onset and the more serious symptoms of the disease 
(Bencze et al., 2006).  Regarding the two cell lines used in this thesis, the male line has 
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longer GAA repeats on both alleles than the female.  Therefore one would expect that 
the male FRDA fibroblasts would make slightly less frataxin and the patient would have 
had an earlier age of onset of FRDA than the female.  Although we do not know the 
exact number of GAA repeats in our normal controls, each cell line came from a normal 
person.  The normal number of repeats is about 66. 
We observed in a long term study (section 1.3.1, Fig. 1.2A) that the FRDA male cell line 
grew more quickly than the matched control.  Then we conducted a second experiment 
to test whether this finding is true for other FRDA fibroblast cell lines.  Therefore a 
female FRDA cell line was used in the second study.  Due to the big difference of 
growth between the FRDA and the control cell line, showed at the time point of the first 
week, we decided to conduct the second study in only one week for the more detailed 
observation.  After one week of growth we found that both male and female FRDA 
fibroblasts grew faster than the matched controls.  There could be several explanations 
for this finding. 
The first one is the number of GAA repeats.  Based on our findings, the GAA repeat 
number can affect cell growth. We grew FRDA fibroblasts with significantly different 
GAA repeat numbers from the controls.  As we stated previously, the FRDA patients 
with lower frataxin expression might be subject to greater oxidative stress or other 
abnormalities associated with FRDA, and therefore the cell growth rate of FRDA is 
affected. 
Secondly, it is the age of the donor when the fibroblasts were harvested for culture.  The 
age of donor affects fibroblast cell growth in culture (Ulrich-Merzenich & Bhonde, 1995).  
In this case the two cell lines of the FRDA patients were matched to appropriate controls 
and were all about the same age, so that we do not think that the age of patient should 
affect growth rate. 
Thirdly, both of the FRDA cell lines were passage number 2 which should mean that they 
should grow normally for many more passages.  Therefore we do not think that passage 
number is affecting growth rate.  
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A significant effort was made to control the GAA repeat length, age and passage number 
by selecting from the cell lines available for purchase.  But in general for the whole 
experiment design, more cell lines from different patients would have to be tested to 
make the results more convincing. 
1.5.2 The level of reactive oxygen species in FRDA is higher than control 
Since cell proliferation is linked to oxidative stress, we started to look at the status of 
oxidative stress through examining the level of ROS.  The ROS generation was tested 
using a well developed optical method immunofluorescence microscopy.  The 
fluorescent dye used in our study (MitoTracker Red CMH2Ros) is specialized for the 
cellular ROS, as it will not fluoresce until oxidized by ROS and sequestered in 
mitochondria (Poot et al., 1996). 
The red fluorescence intensity of MitoTracker Red CMH2Ros represents the level of ROS.  
Chloromethyl-X-rosamine, the oxidized form of MitoTracker Red CMH2Ros, has a 
strong photosensitising action. Therefore, this MitoTracker we used in the experiment is 
not that sensitive to light compared to conventional fluorescent dyes.  
In our results, the red fluorescence intensity was higher in the FRDA than the matched 
control cells as judged by observation of numerous samples.  This might indicate that 
the level of reactive oxygen species in the FRDA is higher than the control.  But before 
drawing this conclusion, one more experiment has to be done in the future, because the 
higher intensity of Mitotracker could be also caused by more mitochondria in the FRDA 
cells than the controls.  In order to answer this question, the intensity of red Mitotracker 
has to be compared with the total number of mitochondria within the same cells.  
Although we did not measure mitochondrial numbers, in the following experiment, 
Rhodamine 123 would be such an ideal marker since it is taken up driven by MMP and 
label all mitochondria.    
These experiments provided evidence for elevated ROS generation in the male FRDA 
fibroblasts. To provide additional support for this interpretation, we also examined the 
cellular ROS defense system in the FRDA cells by testing the activity of Gpx.   
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1.5.3 Glutathione peroxidase (Gpx) activity is higher in the male FRDA fibroblast 
than in the matched control 
Gpx is one of the most important enzymes involved in cellular ROS defense.  By using 
GSH as a reductant, Gpx can convert highly toxic and reactive hydroperoxides (such as 
hydrogen peroxide) into non-toxic and stable water or alcohols (Klotz et al., 2003).  
Therefore, Gpx protects cells against peroxidation.  We measured Gpx activity using an 
assay kit, which should enhance the reliability and reproducibility of the experiment.  
As described in section 1.3.3, the Gpx enzyme activity testing was conducted at 37 °C, 
which is the ideal temperature for enzyme reaction.  The temperature would 
dramatically affect the result, making it either too high to be stable for the enzyme or too 
low to obtain the activity of enzyme.  In this experiment, the temperature was controlled 
and therefore our results cannot be explained by temperature vaiations.   
We found that Gpx activity was higher in the male FRDA fibroblasts than in the matched 
control cells.  Increased Gpx activity represents an adaptive response to elevated 
hydroperoxides and the severe oxidative stress status of FRDA.  Several papers have 
described the Gpx activity in FRDA.  In the frataxin-deficient yeast cells, the Gpx 
activity was 2.3 times higher than the wild type (Auchere et al., 2008).  The Gpx activity 
of blood in FRDA patients was comparable to the controls.  However, there was a 
significant increase of SOD to Gpx activity ratio, which suggested a role for ROS in 
aging (Tozzi et al., 2002).  In the study of Jauslin et al. (2002), the same FRDA cell line 
(GM04078) was used, and the Gpx activity was compared when cells were grown in a 
selenium deficient or selenium supplemented medium (Jauslin et al., 2002).   In the 
medium containing sufficient selenium, the Gpx activity was significantly up-regulated in 
the FRDA cells.  Since we used FBS in our medium, there was likely sufficient 
selenium to permit elevated Gpx activity.  
We found that the Mitotracker experiment indicated that ROS were high in the FRDA 
fibroblasts.  This finding was supported by the high activity of the cellular antioxidant 
enzyme-Gpx activity in the FRDA fibroblasts.  Therefore, connecting these two findings 
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together, the ROS generation in the FRDA fibroblasts induced the elevated activity Gpx 
as an adaptive response to ROS challenge.  
1.5.4 Mitochondrial membrane potential (MMP) is higher in the FRDA fibroblast 
We have shown that the FRDA fibroblasts have high levels of ROS (section 1.4.3) and 
elevated activity of Gpx (section 1.4.2).  MMP was also examined, since it is an 
indicator of mitochondrial function.  MMP was tested by using a selective 
mitochondrial dye, JC-1 (see section 1.3.5).  The transmembrane electrochemical 
gradient, produced by the mitochondrial respiratory chain, has the potential to drive JC-1 
across the inner mitochondrial membrane.  The ratio of monomeric (green) and 
polymeric (red) JC-1 is shown to be an excellent indicator of MMP (see section 1.3.).   
MMP is an important parameter of mitochondrial function that is often used as an 
indicator of oxidant production.  The maintenance of MMP is essential for ATP 
synthesis.  MMP provides motive force for the translocation of protons from 
mitochondrial matrix into the inter-membrane space (Tan et al., 2001).  In general, high 
MMP is associated with more oxidant production (Berg et al., 2002).  Higher MMPs 
indicate that the electron carriers are in a more reduced state increasing the probability of 
electron interactions with molecular oxygen to form superoxide anion.  The formation 
of superoxide anion would subsequently enhance the probability of oxidant production 
(Berg et al., 2002).  In our finding, the MMP of the FRDA fibroblasts was higher than 
the matched control cells (see section 1.3.4).  This high MMP might indicate more 
oxidant production in the FRDA fibroblasts.  Also, the high MMP in the FRDA suggests 
a high level of mitochondrial import capacity and highly efficient mitochondrial function.  
In addition, it might suggest that there is a low demand of ATP, since the MMP would be 
decreased when the energy used for the conversion of ADP to ATP, although this 
contradicts the increased rate of proliferation (Tan et al., 2001).   
The high MMP in the male FRDA fibroblasts indicates that there is more oxidant 
production in the cells.  This finding is consistent with the high level of ROS observed 
in the FRDA cells.  Furthermore, this finding can also explain our observation in the 
cellular oxidant defense system. We have shown that the male FRDA cells had higher 
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antioxidant enzyme activity-Gpx than the controls. This could be explained by the 
adaptive response to the challenge of oxidant production.  
There are no previous studies examining the MMP in FRDA primary fibroblasts. But in 
the FRDA lymphoblasts, the MMP was lower than in the controls, and in frataxin 
knockout yeast, the MMP was also low (Tan et al., 2001).  Although our results in the 
FRDA fibroblasts do not agree with these findings in other FRDA models, our finding 
that the elevated MMP suggesting more oxidant production is consistent with the high 
level of ROS that we observed.  No previous studies compared with the growth rates of 
various FRDA cell lines, therefore we cannot conclude that this male fibroblast line is 
abnormal, but this is a possibility.  The cell line does show three features of FRDA: 1) 
the elevated oxidative stress as seen by the elevated level of ROS, 2) the increased 
activity of antioxidant defense in the cytosol as shown by the increased activity of the 
antioxidant enzyme, Gpx, and 3) more oxidant production as indicated by the enhanced 
MMP. 
In order to clarify whether the MMP is associated with cell cycle progression in FRDA 
fibroblast cells, more experiments need to be done.  In our study, we used a rapidly 
proliferating male FRDA fibroblast cell line, and found it had a high MMP.  So far, we 
cannot draw the conclusion that the high MMP is associated with the high growth rate in 
all FRDA fibroblasts, because we do not know whether the high MMP is affected by the 
sex of donor.  Therefore, this result still needs to be confirmed by more testing on more 
FRDA fibroblast cell lines including both male and female.  For example, MMP needs 
to be tested on at least the female FRDA fibroblast cell line, which was used in this 
project for the short-term growth rate study.  If the MMP from this female FRDA was 
high, it would support the idea that high MMP is correlated with FRDA pathology in 
primary fibroblast cells.     
1.6 Conclusions 
We tested the growth rates of one male and one female primary FRDA fibroblast cell line.  
Each of the FRDA cell lines grew significant faster than its matched normal control cell 
line.  
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We conclude that rapid growth is a feature of FRDA cell lines.  
To test our second hypothesis, we tested Gpx activity, measured oxidant levels and 
determined the MMP.   
We conclude that this cell line exhibits more oxidative stress than control, but we cannot 
conclude that oxidative stress has triggered an increase in the rate of cell cycle 
progression. 
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Chapter 2 Histopathology of FRDA 
2.1 Introduction 
2.1.1 FRDA histopathology  
Spinocerebellar ataxias (SCAs) are genetically inherited disorders with pathology 
symptoms that mostly affect spinal cord and cerebellum (Mascalchi, 2008).  FRDA is an 
SCA that is caused by the deficiency of a mitochondrial protein called frataxin. The 
expression of frataxin is tissue specific and correlated with the main sites of pathology in 
FRDA (Puccio & Koenig, 2000).  The main pathological sites of neurodegeneration in 
FRDA are the dorsal root ganglia, dorsal columns of the spinal cord and dentate nucleus 
of cerebellum (Delatycki et al., 2000) (Koeppen et al., 2007).  Mild degeneration is 
observed in medulla (Puccio & Koenig, 2000).  The histopathologic hallmark in the 
early stages of this disease is atrophy of sensory neurons in the dorsal root ganglia.  This 
loss or even disappearance leads to sensory axonal atrophy in the dorsal columns of the 
spinal cord (Pandolfo, 2008).  Although the sensory nervous system is most severely 
affected, moderate degeneration of the motor system (corticospinal tracts) is found but 
tends to be more severe laterally and distally (Lamarche et al., 1984; Pandolfo, 2008).  
The depletion of nerve fibers slowly progresses from the distal portion of the fiber toward 
its cell body (Lamarche et al., 1984).  Atrophy of the dentate nucleus of the cerebellum 
including loss of neurons and grumose degeneration is usually severe in FRDA (Koeppen 
et al., 2007).  Grumose degeneration is a peculiar proliferation of synaptic terminals in 
dentate nucleus.  The areas of grumose degeneration are highly reactive to ferroportin, 
which is a cytoplasmic iron exporter (Koeppen et al., 2007).  This observation might be 
due to iron accumulation induced biosynthesis of ferroportin in FRDA (Koeppen et al., 
2007).   
The pathological cardiodegeneration in FRDA exhibits hypertrophy of cardiomyocytes in 
the early stage, and followed by loss of these cells with replacement by connective tissue, 
finally leading to heart failure (Pandolfo, 2008). 
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2.1.2. Frataxin deficiency associated cell death in FRDA 
The long GAA repeats decrease the expression of frataxin protein (Pandolfo, 2008), 
which is the cause of FRDA (see section 1.1.1).  Several hypotheses have been proposed 
to explain the consequence of frataxin deficiency: 1) increased oxidative damage; 2) 
induction of mitochondrial iron accumulation; 3) lack of iron sulphur (Fe-S) clusters for 
Fe-S cluster proteins, and 4) subsequently activation of apoptosis.  
Frataxin deficiency clearly leads to oxidative damage to macromolecules such as lipids, 
proteins carbohydrates and nucleic acids (Boonstra & Post, 2004).  This damage would 
subsequently affect proper function of the cells.  FRDA patients exhibit many oxidative 
stress markers such as increased malondialdehyde (lipid peroxidation product) (Emond et 
al., 2000) and increased 8-hydroxy-2’-deoxyguanosine (8OH2’dG, a marker of oxidative 
DNA damage) (Schulz et al., 2000). 
The accumulation of iron has been found within mitochondria in FRDA patients as well 
as frataxin knockout yeast (yfh1p) (Waldvogel et al., 1999) (Babcock et al., 1997) .  
Free iron is very toxic to cells because of its ability to perform Fenton reaction (see 
section 1.1.2.1).  The iron accumulation has been associated with mitochondrial 
dysfunction (Delatycki et al., 2000).   For example, lymphoblasts of FRDA compound 
heterozygotes (FRDA-CH), exhibit low mitochondrial membrane potential (MMP) and 
high levels of filterable free mitochondrial iron but no increase in total mitochondrial iron 
(Tan et al., 2001).  However, the frataxin transfection (FRDA-CH-t) restores the MMP 
and normalizes mitochondrial iron content of FRDA-CH.  Furthermore when challenged 
with free iron, FRDA-CH had an increased total mitochondria iron level and decreased 
MMP, but both can be restored to normal levels in FRDA-CH-t (Tan et al., 2001).  
Therefore, frataxin deficiency increased free mitochondrial iron and decreased MMP in 
FRDA-CH lymphoblasts.  Since these changes can be rescued by frataxin, it is quite 
possible that these changes are associated with the pathophysiological process of FRDA 
as well.  
Although it is clear that accumulation of iron within mitochondria is caused by frataxin 
deficiency, there is still a controversy about the chemical form of the accumulated iron.  
 41
A recently published paper from our lab showed the oxidative state of mitochondrial iron 
accumulated in FRDA fibroblasts, and this was in ferric form but not in free ferrous form 
(Popescu et al., 2007).  Most ferric iron was found to be associated with mitochondrial 
ferritin in FRDA fibroblasts.  
The major function of frataxin protein is related to iron homeostasis such as Fe-S cluster 
assembly (see section 1.1.1).  Thus frataxin deficiency can cause proteins to be starved 
for Fe-S clusters (Pandolfo, 2008).  Fe-S clusters can be found in the electron transport 
chain (complex I, II and III), enzyme catalysis (aconitase) and iron transport 
(ferrochelatase).  Therefore, the absence of the Fe-S clusters can lead to mitochondrial 
dysfunction (Bencze et al., 2006).  The impaired activities of Fe-S cluster-containing 
proteins have been indicated in FRDA patients and in the yeast model of FRDA 
(Pandolfo, 2008).  Accumulation of iron within the mitochondria, deficient activities of 
mitochondrial respiratory complexes I, II and III and aconitase were found in the ∆yfh1p 
mutant (Foury, 1999).  In the presence of an iron chelator, the activity of respiratory 
complexes was restored, while the activity of aconitase remained low.  This suggested 
that the reduced activity of the respiratory complexes was a consequence of excess iron; 
reduction in the activity of aconitase was linked to frataxin deficiency.  This after effect 
is explained through the iron transfer from frataxin to assemble Fe-S cluster, which is the 
active site of proteins such as aconitase (Pandolfo, 2008).  Decreased frataxin 
expression can reduce the synthesis of aconitase, therefore the aconitase reduction can 
not be simply restored by adding iron chelator.  Furthermore, the impaired incorporation 
of iron into iron-sulfur clusters could provide an explanation for iron accumulation in the 
mitochondria of FRDA (Foury, 1999).  In frataxin knock out mice too, the activities of 
Fe-S cluster-containing proteins including complex I, II and III and aconitase were 
decreased (Thierbach et al., 2005).   
It is known that toxic stimuli to cells can activate apoptotic machinery.  The expansions 
of GAA trinucleotide repeats in the frataxin gene result in increased susceptibility of cells 
to oxidant-induced toxicity.  The oxidant-associated mitochondrial stress in FRDA 
fibroblasts has been found to activate the apoptotic cascade (Wong et al., 1999).  A 
significantly higher activity of caspase 3, the central death enzyme of apoptosis, was 
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observed in FRDA compared to control fibroblasts.  This suggests an apoptotic step is 
activated in FRDA fibroblasts.  Furthermore, the treatment with apoptosis inhibitors can 
rescue FRDA but not the control fibroblasts from death, which might suggest a potential 
therapy of FRDA (Wong et al., 1999).  
The frataxin knockout mice have shown increased oxidative stress, reduced activities of 
Fe-S cluster-containing proteins and reduced ATP levels (Thierbach et al., 2005).  All of 
these could lead cells to apoptosis.  Indeed, there are signs of apoptosis found in frataxin 
knockout mice (Thierbach et al., 2005).  Such as the translocation of the apoptotic 
protein Bax to the mitochondria, which is an early apoptotic event.  Furthermore the 
expression of the central death enzyme of apoptosis- caspase 3 was found to be 
up-regulated (Thierbach et al., 2005). 
2.1.3 Pathological effects in FRDA 
The degeneration in the dorsal columns of the spinal cord is correlated with the loss of 
vibratory and positional sense to the FRDA patients, who are progressively affected by 
limb and gait instability, absence of tendon reflexes in the legs and muscle weakness are 
also seen (Delatycki et al., 2000).  Most of the FRDA patients have pes cavus (fixed 
plantar flexion of the foot) and scoliosis (the spine is curved from side to side) (Lamarche 
et al., 1984), while heart disease is always found in FRDA.  The initial symptoms of 
cardiomyopathy are palpitations and shortness of breath caused by hypertrophy of 
cardiomyocytes that thicken the left ventricular wall and septum (Pandolfo, 2008).  
2.1.4 Changes in metal binding proteins 
Frataxin deficiency is associated with abnormal iron metabolism (reviewed by (Gordon, 
2000)).  Recent studies by our lab show abnormal distribution of iron, copper and zinc 
in the FRDA and SCA patients’ spinal cord and medulla (Popescu et al., 2009).  This 
indicates that both iron binding proteins and proteins binding copper or zinc may also be 
affected.  This project focuses on the iron binding protein, ferritin and the copper and 
zinc binding protein, metallothionein.  
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2.1.4.1 Ferritin 
Ferritin functions as an intra-cellular iron storage protein (Aisen et al., 2001).  One 
ferritin molecule is capable of storing up to 4500 ferric iron atoms.  Therefore ferritin 
can keep iron in a non-reactive form and still be bioavailable when needed for cell 
function (Aisen et al., 2001).  Two subunits of mammalian ferritin are heavy (H) chain 
and light (L) chain.  The function of the two subunits is distinct.  H chain can oxidize 
active ferrous to relatively inert ferric iron.  While L chain works as the long-term iron 
storage (Ill et al., 2006).  The distribution of these two subunits is not homogeneous in 
the brain.  H-ferritin is mainly localized in neurons and L-ferritin is found in microglia, 
while the mix of H and L can be found in oligodendrocytes (Ill et al., 2006).  
Mitochondrial ferritin (MtF) has a similar sequence as cytosolic H-ferritin.  Functionally, 
like the cytosolic L-ferritin, mitochondrial ferritin plays a role in storing mitochondrial 
iron (Campanella et al., 2004).  In frataxin deficienct yeast cells, MtF expression can 
restore the decreased Fe-S cluster-containing protein activities and prevent the 
progression of mitochondrial iron accumulation (Campanella et al., 2004).    
Expression of ferritin is regulated at the level of protein translation (Aisen et al., 2001).  
Ferritin mRNA contains an iron responsive element (IRE), a stem-loop structure, in the 
5’ untranslated region, which is recognized and bound by iron regulatory protein (IRP) 
(Aisen et al., 2001).  When there is high intracellular iron, IRP has an Fe-S cluster and 
thus is unable to bind to IRE in the mRNA of ferritin.  Therefore the translation can 
occur to synthesize ferritin.  Under low iron conditions, IRP can bind to IRE thereby 
blocking the translation pathway.  The cytosolic ferritin levels in FRDA hearts were not 
significantly higher than normal (Michael et al., 2006) but there was enhanced density of 
ferritin within mitochondria and lysosomes of the FRDA heart (Michael et al., 2006). 
2.1.4.2 Metallothionein 
Metallothioneins (MT), a family of metal binding proteins, are one of the most important 
proteins with a high affinity for the transition metals copper and zinc.  Four isoforms 
have been identified in mammals (Stankovic et al., 2007).  MT-I and MT-II are 
ubiquitously expressed in most mammalian tissues.  The regulation and production of 
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MT-I and MT-II are coordinated and therefore they are usually described as one 
functional entity- MT-I+II (Penkowa, 2006).  MT-III, also called growth inhibitory 
factor (GIF), is expressed mainly in the brain.  MT-IV is expressed in squamous 
epithelial cells whereas it is not detectable in the brain (Hidalgo et al., 2001).  This 
project will focus on the best described MT proteins: MT-I+II.  
In the central nervous system, MT-I+II is mainly expressed in astrocytes; nevertheless it 
can also be found in endothelial cells of blood vessels, meningeal cells of pia mater, 
ependymal cells, and epithelial cells of choroids plexus.  But there is less expression in 
microglia, oligodendrocytes and neurons (Hidalgo et al., 2001).  The function of 
MT-I+II is associated with multipurpose neuroprotective actions such as metal 
detoxification, cell survival and free radical scavenging (Penkowa, 2006).  In MT-I+II 
double knock out mice, decreased level of MT-I+II led to impaired recovery from heavy 
metal toxicity or oxidative stress (Miles et al., 2000).  Metals and reactive oxygen 
species (ROS) can also induce the increase of MT-I+II expression through activating 
MT-I+II gene transcription as well as post-transcriptional regulation (West et al., 2008).  
Treatment with exogenous MT can significantly prevent demyelination and axonal 
damage in a multiple sclerosis rat model (Penkowa & Hidalgo, 2003).  In central 
nervous system (CNS) pathology models such as Parkinson’s Disease (PD) and 
Alzheimer’s Disease (AD), MT-I+II expression was found to be increased (Penkowa, 
2006). 
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2.2 Research Objectives and Hypotheses: 
Hypothesis: Metal binding proteins will have abnormal distribution in FRDA or 
Spinocerebellar ataxia (SCA). 
Research Objectives: 
1. To determine the histopathology associated with FRDA and SCA compared to 
normal controls, 
2. To determine the distribution of metal binding proteins in spinal cord and medulla of 
FRDA, SCA, normal controls, and disease controls. 
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2.3 Methods 
2.3.1 Clinical information 
2.3.1.1 Ataxia control 
An ataxia control (labelled SCA in figures) was from a 44 year old female with a possible 
diagnosis of FRDA but with clinical information that was more in line with 
spinocerebellar ataxia (SCA).  Genetic testing for FRDA tri-nucleotide repeats and 
available testing for SCA were negative.  Since the pathology was somewhat consistent 
with FRDA, the pathologist suggested FRDA resulted from point mutations in the 
frataxin gene or a disorder of vitamin E metabolism.  The tissues were formalin fixed 
cervical spinal cord and medulla with a post mortem interval (PMI) of 3 hours.  The 
tissues were purchased from the Brain and Tissue Bank for Developmental Disorders of 
the National Institute of Child Health and Human Development.  
2.3.1.2 FRDA cases 
Two FRDA cases were examined. The first (labelled FRDA2) was from a 33 year old 
female with extensive demyelination of the posterior columns and the lateral 
corticospinal tracts consistent with FRDA.  The tissues available were formalin fixed 
lumbar spinal cord with a PMI of 21 hours.  The tissues were purchased from the 
Human Brain and Spinal Fluid Resource Centre. 
The second case (labelled FRDA3) was from a 25 year old female with a diagnosis of 
FRDA but no clinical information.  The tissues available were formalin fixed cervical 
spinal cord and medulla.  The PMI is between 13 hours to 37 hours.  The tissues were 
purchased from the Douglas Hospital Research Centre Brain Bank. 
2.3.1.3 Normal control cases 
Four normal control cases were examined. The first case (labelled control 1 of spinal cord 
and control 1 of medulla) was from a 42 year old female.  The tissues available were 
formalin fixed cervical spinal cord and medulla with a PMI of 4 hours.  The tissues were 
purchased from the Brain and Tissue Bank for Developmental Disorders of the National 
Institute of Child Health and Human Development.   
The second case (labelled control 2 of spinal cord) was from a 23 year old female.  The 
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tissues available were formalin fixed lumbar spinal cord with a PMI of 19 hours.  The 
tissues were purchased from the Human Brain and Spinal Fluid Resource Centre. 
The third case (labelled control 3 of spinal cord and control 2 of medulla) was from a 41 
year old female.  The tissues available were formalin fixed cervical spinal cord and 
medulla with a PMI of 28.75 hours.  The tissues were purchased from the Douglas 
Hospital Research Centre Brain Bank. 
The fourth case (labelled control 3 of medulla) was a male craniocerebral trauma.  The 
tissues available were medulla with a PMI of 10.5 hours.  The tissues were purchased 
from the Movement Disorders Clinic Saskatoon Health Region.  The ethics approval 
number is BioReb-250. 
The summary of the availabity of tissues used in this project is shown in Table 2.  The 
sex is not marked in the table, since most samples are females except the control 3 of 
medulla. 
2.3.1.4 Disease controls  
All the disease controls were from the Movement Disorders Clinic Saskatoon Health 
Region.  The ethics approval number is BioReb-250.  The disease controls were: male 
Parkinsons’s Disease (PD); female Alzheimer’s Disease (AD); male Progressive 
Supranuclear Palsy (PSP). 
2.3.2 Hematoxylin and eosin stain (H&E stain) 
H&E staining was done according to (Grethen, 1967).  The formalin fixed tissues were 
embedded in paraffin, and then sectioned. All the sections, 8 micron in thickness, were 
deparaffinized with two changes of xylene for 3 minutes each time followed by 1 minute 
of 1:1 xylene-100% alcohol, 1 minute in each of 95%, 80% and 70% ethanol. The slides 
were washed in 0.03M phosphate buffered saline (PBS) for 20 minutes, rinsed in running 
tap water and distilled water for 1 minute each.  The slides were stained with Ehrlich 
hematoxylin for 4 minutes.  In order to remove the extra stain the slides were washed 
under tap water, and rinsed in distilled water.  The slides were dipped in 1% acid 
alcohol, and then washed in running tap water for 7 minutes, followed by rinsing the 
slides in distilled water.  The slides were stained in 0.1% alcoholic eosin for 1 minute, 
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before immersing in 70% and 95% alcohol for 1 minute, respectively.  The sections 
were transferred into two changes of 100% alcohol for 1 minute each, and then 
alcohol/xylene solution for 3 minutes, finally cleared in two changes of xylene for 5 
minutes each.  
2.3.3 Myelin staining  
Luxol fast blue staining protocol is based on the procedure of (Grethen, 1967).  The 
deparaffinized sections were immersed in 0.03M PBS for 30 minutes.  The slides were 
left in freshly filtered Luxol fast blue solution (see appendix) at 60°C for 3 hours.  The 
extra stain was removed by rinsing slides in distilled water.  In order to get the 
maximum contrast between grey and white matter, the slides were differentiated in 1/16 
strength lithium carbonate solution for 30 seconds and then quickly dipped in 70% 
ethanol.  This procedure was repeated until good contrast was achieved.  When the 
differentiation was completed, the slides were put back into distilled water, and 
counter-stained in cresyl violet solution (see appendix) for 40 minutes.  After stainging, 
the slides were quickly dipped in each of 70% and 95% ethanol for about 10 seconds, and 
then dehydrated in two changes of iso-propyl alcohol for 3 minutes each change, finally 
quickly washed in xylene/ 100% alcohol, and xylene prior to mounting with Permount 
mounting medium. 
2.3.4 Immunohistochemistry 
The deparaffinised sections were washed in 0.03M PBS, PH 7.4, and then incubated in 
0.1% trypsin at room temperature for 10 minutes.  The sections were put into 0.03M 
PBS for 30 minutes.  The slides were incubated in the blocking buffer (3.0% fat free 
milk plus 0.1% Triton X-100 in 0.03M PBS) for 30 minutes.  The primary antibody was 
diluted in the buffer (1% fat free milk plus 0.1% Triton X-100 in 0.03M PBS), and 
overnight incubations were at 4 C.  The dilutions for primary antibodies are shown in 
table 2.  All of the primary antibodies were tested by the FRDAs, SCA and the matched 
normal controls. In the meantime, the negative controls (no primary but secondary 
antibody only) for each tissue case were examined. The slides were washed with 0.03M 
PBS three times, for 10 minutes each time, and then re-blocked with the blocking buffer 
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for 30 minutes.  Biotin-conjugated secondary antibodies listed in Table 2 were all 
diluted in 1: 200 and incubated with the slides at room temperature for 30 minutes.  In 
order to saturate endogenous peroxides, the slides were treated with 3% H2O2 in methanol 
for 15 minutes, and then blocked with the detergent-free blocking buffer for 30 minutes.  
The secondary antibodies were detected by using an avidin-biotin kit (Vector 
Laboratories).  The ABC solution (8μL buffer A plus 8 μL buffer B in 1ml PBS) was 
prepared 30 minutes before use.  The sections were incubated in the ABC solution at 
room temperature for an hour.  After rinsing with 0.03M PBS, PH 7.4, the slides were 
incubated in 0.175M sodium acetate for 10 minutes.  The sections were then incubated 
for 5 minutes in diaminobenzidine solution (DAB) (Vector Laboratoies) according to the 
kit instructions (2 drops of buffer, 4 drops of DAB and 2 drops of H2O2 in 5mL PBS).  
The reaction was stopped by incubating sections in 0.175M sodium acetate for 10 
minutes, and then washed once in 0.03M PBS.  The slides were dehydrated for 5 
minutes, in each of 70%, 80% and 95% of ethanol, then cleared in xylene/ethanol, 
followed by two changes of xylene for 15 minutes, and finally mounted with Permount 
mounting medium. 
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Table 2.  Antibodies for immunohistochemistry 
Primary Secondary 
Name / Type Source Antigen Dilution Name  Source Dilution
Metallothionein 
(MT) 
Monoclonal 
QED Bioscience, 
San Diego, CA 
MT-I 
MT-II 
1:250 Biotin 
conjugated 
Anti-mouse 
Vector 
  Burlingame, 
CA 
1:200 
Ferritin 
Polyclonal 
Abcam Ltd, 
Cambridge Science 
Park, UK 
H and L ferritin 1:250 Biotin 
conjugated 
Anti-sheep 
Vector 
  Burlingame, 
CA 
1:200 
Frataxin 
Polyclonal 
Santa Cruz Frataxin 
Peptide antigen 
1:20 Biotin 
conjugated 
Anti-rabbit 
GFAP Dako Crop. , 
Carpinteria, CA 
GFAP astrocytes 1:8000 Biotin 
conjugated 
Anti-rabbit 
NF-200 Sigma, 
St Louis, MO 
Neurofilaments 1:1000 Biotin 
conjugated 
Anti-rabbit 
 
 
 
Vector 
  Burlingame, 
CA 
 
 
 
 
1:200 
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2.4 Results: 
In most cases the difference between control and affected tissue was obvious.  Therefore 
the quantification was done only when the control and affected tissue looked similar. 
2.4.1 Spinal cord 
Spinal cord is one of the areas that are most severely affected in Friedreich ataxia.  
Therefore, spinal cords from 3 different controls (control 1, 2 and 3) and an ataxia (SCA) 
that was not FRDA were compared to spinal cords from two different FRDA patients 
(FRDA 2 and 3).  More clinical information on each sample is found in section 2.3.1. 
2.4.1.1 General pathology 
2.4.1.1.1 Luxol fast blue histology 
Luxol Fast Blue staining showed myelinated axons in the white matter of the spinal cord.  
SCA and control 1, FRDA2 and control 2, FRDA3 and control 3 (Fig. 2.1, 2.2, 2.3) are 
sex, age and post mortem interval (PMI) matched spinal cords.  The dorsal columns of 
SCA, FRDA2 and FRDA3 (Fig. 2.1 B, Fig. 2.2 B, Fig. 2.3B) showed fewer myelinated 
axons than the controls (Fig. 2.1 A, Fig. 2.2 A, Fig. 2.3 A), which indicated 
demyelination.  In contrast, the myelinated axons in the ventral columns of SCA, FRDA 
2 and FRDA 3 (Fig. 2.1 D, Fig. 2.2 D, Fig. 2.3 D) showed less demyelination than the 
controls (Fig. 2.1 C, Fig. 2.2 C, Fig. 2.3 C).  No degenerative changes were seen in the 
grey matter and other regions of the white matter in the spinal cords (data not shown).  
2.4.1.1.2 Neurofilament 200   
An antibody to the 200 kD polypeptide of intermediate filaments from neurons (NF 200) 
was used to localize axons and neuronal cell bodies that contain this type of 
neurofilament polypeptide.  
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Fig.2.1 Demyelination in SCA spinal cord.  
Spinal cord stained by Luxol Fast Blue exhibited many not much myelinated axons in the 
dorsal columns of SCA (B) compared with the dorsal columns of control 1(A).  But 
there were fewer amount of myelinated axons in the ventral columns of SCA (D) than the 
ventral columns of control 1 (C). Scale =50 µm. 
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 Fig.2.2 Demyelination in FRDA 2 spinal cord.  
Spinal cord stained by Luxol Fast Blue exhibited less myelinated axons in the dorsal 
columns of FRDA 2 (B) than control 2 (A). There were fewer not less myelinated axons 
in the ventral columns of FRDA 2 (D) than control 2 (C).  (A) Myelinated axons in the 
dorsal columns of control 2 (B) Myelinated axons in the dorsal columns of FRDA 2 (C) 
Myelinated axons in the ventral columns of control 2 (D) Myelinated axons in the ventral 
columns of FRDA 2. Scale =50 µm. 
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Fig.2.3 Demyelination in FRDA 3 spinal cord. 
Spinal cord stained by Luxol Fast Blue exhibited fewer not less myelinated axons in 
dorsal columns of FRDA 3 (B) than control 3 (A).  There were fewer myelinated axons 
in the ventral columns of FRDA 3 (D) than control 3 (C).  (A) Myelinated axons in the 
dorsal columns of control 3 (B) Myelinated axons in the dorsal columns of FRDA 3 (C) 
Myelinated axons in ventral columns of control 3 (D) Myelinated axons in ventral 
columns of FRDA 3. Scale =50 µm. 
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The dorsal columns of the spinal cord in control 1 (Fig. 2.4A) showed a large number of 
evenly spaced spots representing neurofilament 200-positive axons.  In contrast, the 
dorsal columns of SCA showed a smaller number (reduced density) of axons with a large 
amount of neurofilament 200-negative material.   
The ventral columns of the control 1 spinal cord (Fig. 2.4 C) also showed evenly spaced, 
but larger, axons than seen in its dorsal columns (Fig. 2.4 A).  In comparison to the 
ventral columns of control 1, the ventral columns of SCA (Fig. 2.4 D) showed evenly 
spaced axons that stained slightly less than the normal ventral columns.  NF-200 
positive axons were counted within a standard area of each image.  Quantification 
showed that in the dorsal columns, the number of axons per unit area was fewer in SCA 
(2 axons/unit area) compared to control 1 (107 axons/unit area).  Although visually, the 
number of axons in the ventral columns of SCA and control 1 looked similar, 
quantification showed that there was a lower number of axons in SCA (33 axons/unit area) 
compared to control 1 (52 axons per unit area). 
The control 2 dorsal columns (Fig. 2.5 A) of spinal cord showed a large number of evenly 
spaced axons.  In contrast, the positive spots of axons in the dorsal columns of FRDA 2 
(Fig. 2.5 B) were barely seen.  The ventral columns of the control 2 (Fig. 2.5 C) also 
showed evenly spaced, but fewer axons than its dorsal columns (Fig. 2.5 A).  In 
comparison to the ventral columns of control 2, the ventral columns of FRDA 2 (Fig. 2.5 
D) showed unevenly spaced but fewer axons.  Quantification was not done because the 
difference between FRDA and control was obvious. 
The dorsal columns of the control 3 (Fig. 2.6 A) showed a large number of evenly spaced 
axons.  In contrast, there were no detectable NF 200 positive axons in the dorsal 
columns of FRDA 3 (Fig. 2.6 B).  The ventral columns of the control 3 (Fig. 2.6 C) also 
showed evenly spaced, but larger axons than seen in its dorsal columns (Fig. 2.6 A).  
The ventral columns of the FRDA 3 (Fig. 2.6 D) showed evenly spaced, but fewer axons 
than the ventral columns of control 3.  Quantification was not done because the 
difference between FRDA and control was obvious. 
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NF 200 staining in the grey matter of the spinal cord was variable between the three 
controls (Fig. 2.7 A-F).   Although axons were stained in all of the three, the best 
staining of the neuronal cell bodies was for control 3, with reduced or little stained axons 
in controls 1 and 2.  Compared with the dorsal and the ventral horns of control 1, we 
saw fewer axons staining in the ventral horns, but the axons were always evenly spaced 
(Fig. 2.7 A, B).  The neuron bodies (white arrows) were not positively stained in the 
grey matter of control 1(Fig. 2.7 A and B).  In the grey matter of control 2, there were 
only a few detectable NF 200 positive axons (black arrows) in the dorsal horns (Fig. 2.7 
C) and ventral horns (Fig. 2.7 D) close to the central grey matter.  The neurons (white 
arrows) in the control 2 (Fig. 2.7 C and D) were NF 200 positive.  In the dorsal horns 
near to the central grey matter (Fig. 2.7 E) of control 3, the axons (black arrows) were 
evenly spaced but less than its ventral horns near to the central grey matter (Fig. 2.7 F). 
The neurons of control 3 (white arrows) stained positively (Fig. 2.7 F).  
NF-200 staining was also not consistent in the FRDA samples: FRDA 2 showed staining 
of axons and neurons but FRDA 3 seemed to be degraded or vacuolated.    
In comparison to the three controls, the dorsal horns of FRDA 2 did not show any 
detectable axons (Fig. 2.7 G), but had a few positive axons in the ventral horns near to the 
central grey matter (Fig. 2.7 H).   The neurons (white arrows) (Fig. 2.7 H) in the grey 
matter of FRDA 2 were positive.  In the grey matter of FRDA 3, the axons were not 
seen in the dorsal horns (Fig. 2.7 I), but a few axons were seen in the ventral horns (Fig. 
2.7 J), which was less than in the normal ventral horns.  Similar to FRDAs, SCA did not 
show any positive axons in the dorsal horns (Fig. 2.7 K).  In SCA, there were more 
evenly-spaced axons than in the FRDA ventral horns (Fig. 2.7 L).  Unlike FRDA 2, the 
neuron bodies (white arrows) of SCA did not stain NF 200 (Fig. 2.7 L). 
There was loss of axons in the dorsal columns and the dorsal horns of the FRDAs spinal 
cord and SCA.  This result is consistent with our finding about the demyelination and 
loss of fibers in the dorsal columns in these FRDAs and SCA.  
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Fig.2.4 NF 200 localization in the white matter of SCA and control 1 spinal cord.  
There were fewer axons in the dorsal columns of SCA spinal cord (B).  In the ventral 
columns, the amount of axons of SCA was less than in control 1. 
(A) dorsal columns of control 1 (B) dorsal columns of SCA (C) ventral columns of 
control 1 (D) ventral columns of SCA.  Black arrows: myelinated axons. Scale =50 µm. 
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Fig.2.5 NF 200 localization in white matter of control 2 and FRDA 2 of spinal cord.  
NF 200 was localized within axons in the white matter of the spinal cord.  There were 
undetectable NF 200 staining axons in the dorsal columns of FRDA 2 spinal cord (B), 
and the ventral columns of FRDA 2 (D) exhibited many, not much axons compared to the 
ventral columns of control 2 (C). 
(A) dorsal columns of control 2 (B) dorsal columns of FRDA 2 (C) ventral columns of 
control 2 (D) ventral columns of FRDA 2.  Black arrows: axons. Scale =50 µm. 
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Fig.2.6  NF 200 localization in the white matter of control 3 and FRDA3 of spinal cord.  
NF 200 was localized within axons in the white matter of the spinal cord.  There were 
few axons in the dorsal columns of FRDA 3 spinal cord (B).  The ventral columns of 
FRDA 3 (D) was less affected but had reduced numbers of NF200-stainable axons 
compared to control 3. 
(A) dorsal columns of control 3 (B) dorsal columns of FRDA 3 (C) ventral columns of 
control 3 (D) ventral columns of FRDA 3.  Black arrows: axons. Scale= 50µm. 
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Fig.2.7 NF 200 localization in grey matter spinal cord.  
(Figure legend continues to the next page) 
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NF 200 was localized within axons in the grey matter of the spinal cord of controls (Fig. 
2.7 A-F), FRDAs (Fig. 2.7 G-J) and SCA (Fig. 2.7 K-L).  The best staining of neuronal 
cell bodies was for control 3 (Fig. 2.7 F) and FRDA 2 (Fig. 2.7 H), with reduced or little 
in controls 2 and 1 (Fig. 2.7 B, D) and the SCA (Fig. 2.7 L).  There were many fewer 
myelinated axons in the dorsal horns of FRDAs and SCA spinal cord (G, I, K).  A few 
axons were seen in the ventral horns of FRDAs (Fig. 2.7 H, J).  While the SCA 
exhibited more evenly-spaced axons than in the ventral horns of FRDA (Fig. 2.7 L).  
Dorsal horns of spinal cord: control 1 (A), control 2 (C), control 3 (E), FRDA 2 (G), 
FRDA 3 (I) and SCA (K).  Ventral horns of spinal cord:  control 1 (B), control 2 (D), 
control 3 (F), FRDA 2 (H), FRDA 3 (J) and SCA (L) Black arrows: myelinated axons.  
White arrows: neurons. Scale=100 µm. 
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2.4.1.1.3 Glial fibrillary acid protein 
The full scan of glial fibrillary acid protein (GFAP) localization in the control 1 spinal 
cord (Fig. 2.8 A) showed that GFAP was found in the whole white matter as well as the 
dorsal horns of the grey matter.  The full scan of SCA (Fig. 2.8 B) showed that GFAP 
was evenly localized in most areas of the white matter.  But it was especially elevated in 
the dorsal columns of the white matter and the dorsal horns of the grey matter.  The high 
magnification picture of the dorsal horns of control 1 (Fig. 2.8 C) presented light brown 
staining of GFAP.  In contrast, the GFAP staining in the dorsal horns of SCA (Fig. 2.8 
D) was much darker, and the cellular processes were more prominent.  
The full scan of GFAP localization in the control 2 spinal cord (Fig. 2.9 A) showed that 
GFAP was evenly localized in the whole white matter and the grey matter.  The full 
scan of FRDA 2 (Fig. 2.9 B) showed the GFAP was evenly localized in most areas of the 
white matter and the grey matter.  But it was elevated in the dorsal columns of the white 
matter and the dorsal horns adjacent to the central grey matter.  The high magnification 
picture of the dorsal horns in control 2 (Fig. 2.9 C) presented evenly spaced GFAP.  In 
comparison to control 2, the dorsal horns near to the central grey matter of FRDA 2 (Fig. 
2.9 D) showed evenly spaced GFAP including some large dark brown reactive astrocytes 
(black arrows) in between. 
There was astrocyte gliosis in the dorsal horns and the dorsal columns of both FRDA 2 
and SCA.  Furthermore, FRDA 2 had more reactive astrocytes than SCA and the 
controls. 
2.4.1.2 Metal binding proteins 
2.4.1.2.1 Frataxin 
We found that both the SCA and the FRDA had demyelination in the dorsal columns, 
evidence of gliosis (see section 2.4.1.1.3) and loss of axonal fibres (see section 2.4.1.1.1 
and 2.4.1.1.2).  Although there are similarities between these two ataxias, we know that 
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Fig.2.8 GFAP localization in the dorsal horns of the spinal cord.  
(A) Full scan of GFAP localization in control 1.  (B) Full scan of GFAP localization in 
SCA (C) GFAP localized in the dorsal horns of control 1.  (D) GFAP localized in the 
dorsal horns of SCA. Scale (A, B) =2 mm 
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Fig.2.9 Reactive astrocytes in the dorsal horns of FRDA 2 spinal cord.  
There were more reactive astrocytes (black arrows) presented by GFAP in the dorsal 
horns of the FRDA2 spinal cord than control 2. (A) Full scan of GFAP localization in 
control 2.  (B) Full scan of GFAP localization in FRDA.  (C) GFAP localized in dorsal 
horns of control 2.  (D) GFAP localized in dorsal horns of FRDA 2. Scale (A, B) =2 
mm. 
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the cause of SCA is different from FRDA.  FRDA results from a deficiency of frataxin, 
therefore we used anti-frataxin antibodies to distinguish between these two and to 
examine the localization of this iron binding protein. 
In the dorsal columns of the three controls (Fig2.10A -C), fraxatin was seen in the 
myelinated axons (black arrows).  Furthermore, in control 2, it also stained a few glia 
(white arrow).  Although the loss of axons in the dorsal columns was also found in SCA, 
there was frataxin in the myelinated axons (Fig. 2.10D, black arrows).  In contrast, 
FRDA 2 and 3 (Fig. 2.10 E, F) showed undetectable frataxin in the dorsal columns of 
spinal cords.  
In the normal ventral columns (Fig. 2.11 A-C), frataxin was found in the myelinated 
axons (black arrows) as well as the glial cells (white arrows).  Frataxin in the ventral 
columns of SCA (Fig. 2.11 D) was found in the myelinated axons (black arrows) and the 
glial cells (white arrows).  FRDA 2 and 3 (Fig. 2.11 E, F) showed undetectable frataxin 
in the ventral columns of the spinal cord.  Therefore, only FRDAs had the low frataxin 
in the ventral columns of the spinal cords; frataxin was found in the myelinated axons 
and the glial cells in the three controls and the ataxia control (SCA).  
Frataxin was localized within neurons in the grey matter of the spinal cord in both the 
unaffected controls (Fig 2.12 A-C) and the ataxia control (Fig 2.12 D).  FRDA 2 (Fig. 
2.12 E) had much less frataxin.  The heavy frataxin reactivity was seen associated with 
the medium sized, spindle-shaped cells in FRDA 3 (Fig. 2.12 F), which seemed to be 
abnormally shaped for neurons.  This staining may be an artifact.  In the controls, 
frataxin was mainly found in the neurons and was seen in glia. 
There was less frataxin in FRDA 2 than the SCA (Fig.2.12 D), but the SCA had a similar 
level of frataxin as the controls.  
We saw reduced frataxin levels in the FRDA cells confirming the diagnosis of FRDA.   
The very high level of frataxin in the SCA confirmed that this SCA of unknown type 
could not be FRDA. 
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Fig.2.10 Frataxin in the dorsal columns of spinal cord. 
(A-D) Frataxin was found in myelinated axons (black arrows) in the dorsal columns of 
spinal cord. In control 2 (B), it also stained a few glia (white arrow).  (E-F) There was 
lack of frataxin in the dorsal columns of the spinal cord. 
(A-C) normal controls: (A) Control 1 (B) control 2 (C) control 3  
(D-F) ataxias: (D) SCA (E) FRDA 2 (F) FRDA 3.  Scale=50 µm. 
 
 
 
 67
  
Fig.2.11 Frataxin in the ventral columns of spinal cord. 
(A-C) normal controls: (A) Control 1 (B) control 2 (C) control 3  
(D-F) ataxias: (D) SCA (E) FRDA 2 (F) FRDA 3 
(A-D): Frataxin was found in myelinated axons (black arrows) as well as glial cells 
(white arrows) in the ventral columns of the spinal cord. (E-F): There was lack of frataxin 
in the dorsal columns of the spinal cord.  Scale=50 µm. 
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Fig.2.12 Frataxin in grey matter of spinal cord. 
(A-C) controls: (A) control 1; (B) control 2; (C) control 3. (D-F) diagnosis of ataxias.  
(D) SCA. (E) FRDA 2. (F) FRDA 3. 
(A-C) Frataxin was mainly seen in neurons, and was found in glia.  (D) Frataxin level 
was not reduced in SCA.  (E) Frataxin was reduced in FRDA2.  (F) Frataxin was found 
in the grey matter of the spinal cord with abnormal shaped neurons. Black arrows: glial 
cells.  White arrows: neurons. Scale=50 µm. 
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2.4.1.2.2 Metallothionein-I+II localization in spinal cord of ataxias and controls 
We found that the MT was undetectable in either FRDA or SCA but was clearly seen in 
the two controls in both the grey matter and the dorsal horns (Fig. 2.13, 2.14).  
The full scan of control 1 (Fig. 2.13A) showed the MT-I+II was localized in the dorsal 
horns and the ventral horns of the spinal cord, but not in the SCA spinal cord (Fig. 2.13B).  
The MT-I+II was found within the glial cells (black arrows) but not the neurons in the 
dorsal horns of control 1 spinal cord (Fig. 2.13C).  The MT-I+II in the SCA was not 
detectable even in the high magnification image (Fig. 2.13D). 
The full scan of control 2 (Fig. 2.14A) showed that the MT-I+II localized in the dorsal 
and the ventral horns of the spinal cord.  In contrast, FRDA 2 spinal cord did not show 
MT in either the dorsal or the ventral horns (Fig. 2.14B).  In the high magnification 
image of control 2 (Fig. 2.14C), the MT-I+II was seen in the dorsal (Fig. 2.14C) and the 
ventral horns (Fig. 2.14D).  Similar as what we found in the SCA, no MT-I+II was 
detected in FRDA 2 spinal cord (Fig. 2.14E).  
Both FRDA 2 and SCA had low level of MT-I+II that can not be detected in our study.  
All the controls had some MT-I+II located in the dorsal horns.  Therefore, MT-I+II 
deficiency was found in FRDA 2 and SCA spinal cord. 
2.4.1.2.3 Ferritin 
Ferritin was not detected in either the dorsal (Fig. 2.15B) or the ventral columns (Fig. 
2.15D) in FRDA 2.   In the dorsal and the ventral columns of control 2, ferritin was 
mainly localized within the glial cells (Fig. 2.15A, C black arrows), but also in the blood 
vessel walls (bold arrows).  FRDA 3 did not show any detectable ferritin in either the 
dorsal (Fig. 2.16B) or the ventral columns (Fig. 2.16D).  In control 3, ferritin was 
mainly localized within the glial cells (black arrows) in the dorsal (Fig. 2.16A) and the 
ventral columns (Fig. 2.16C). 
SCA (Fig. 2.17B) showed a large amount of ferritin in the blood vessel walls (bold 
arrows) and a little ferritin was also localized within the glial cells (black arrows) of the 
dorsal columns.  In contrast, ferritin was mainly localized within the glial cells (black 
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arrows) in the ventral columns of SCA (Fig. 2.17D).  In control 1, ferritin was mainly 
localized within the glial cells in the dorsal columns (Fig. 2.17A) and the ventral columns 
(Fig. 2.17C). 
Both the three controls and FRDA 2 and 3 (Fig. 2.18E, F) exhibited ferritin in the glial 
cells (black arrows) and the neurons (white arrows) of the grey matter (Fig. 2.18B, C), 
but more of the glial cells stained for ferritin in the controls.  A little different 
distribution of ferritin was seen in control 1 (Fig. 2.18A): Ferritin was also localized 
within some blood vessel walls (bold arrows), but not in the neurons (white arrows).  In 
the grey matter of SCA (Fig 2.18D), abundant ferritin was found within the blood vessel 
walls and the glial cells.  This was not been seen in the two FRDA cases.  
The two FRDAs had undetectable ferritin in either the dorsal or the ventral columns of 
spinal cord.  But in the normal controls, most ferritin was localized within the glial cells; 
a little ferritin was found within the blood vessel walls in both the dorsal and the ventral 
columns.  SCA had a very unusual ferritin distribution in the dorsal columns.  Most 
ferritin was found within the blood vessel walls instead of the glial cells only in the dorsal 
columns of SCA, while the ventral columns remained as normal as the controls. 
2.4.2. Medulla 
2.4.2.1. Metal binding proteins 
2.4.2.1.1 Frataxin localization in medulla of ataxias and controls 
Frataxin deficiency is the cause of Friedreich Ataxia.  Here we examined the frataxin in 
the olivary nuclear complex (ONC), which is one of the most affected regions of FRDA 
medulla.  
FRDA 3 medulla (Fig. 2.19H) had a low level of frataxin in the neurons or the glial cells 
in the ONC of medulla.  Frataxin was seen within the neurons (black arrows) of the 
ONC in control 1, 2 and 3 medulla (Fig. 2.19A-C) and all the disease controls (PD: Fig. 
2.19D, AD: Fig. 2.19 E and PSP: Fig.2.19 F).  In SCA medulla (Fig. 2.19.G), the level 
of frataxin in neurons was high compared to FRDA 3, and was about the same as the 
controls and the disease controls.  Frataxin was found not only in the SCA neurons  
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Fig.2.13 Metallothionein-I+II was localized in glial cells of dorsal horns in control 1 but 
not in SCA spinal cord. 
(A) and (B) full scan of MT-I+II spinal cord.  (C) MT-I+II was localized within glial 
cells (black arrows) in the dorsal horns of the control spinal cord.  (D) There was less of 
MT-I+II in the dorsal horns of SCA. Scale (A, B) =2 mm. 
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 Fig.2.14 Metallothionein-I+II localization in glial cells of grey matter in control 2 but not 
FRDA 2 spinal cord.  
(A) and (B) full scan of MT-I+II spinal cord.  (C) MT-I+II was localized in the dorsal 
horns of control 2 spinal cord.  (D) MT-I+II was localized in the ventral horns of control 
2 spinal cord.  (E) There was less of MT-I+II in the dorsal horns of FRDA 2.  Scale (A, 
B) =2 mm. 
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Fig.2.15 Ferritin was visualized in the white matter of control 2 spinal cord, but not FRDA 
2. 
Ferritin was not detectable in dorsal columns (B) or ventral columns (D) of FRDA 2. 
Ferritin was mainly localized within glial cells (black arrows) in dorsal columns (A) and 
ventral columns (C) of control 2.  Little ferritin was localized in blood vessel walls (bold 
arrows).  Black arrows: glial cells.  Bold arrows: blood vessels.  Black arrows: glial 
cells. Scale =50 µm. 
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Fig.2.16 No ferritin was detected in FRDA 3 spinal cord   
FRDA 3 spinal cord did not show any detectable ferritin in either the dorsal columns (B) 
or the ventral columns (D). Ferritin was mainly localized within glial cells (black arrows) 
in dorsal columns (A) and ventral columns (C) of control 3 spinal cord. Black arrows: 
glial cells. Scale =50 µm. 
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 Fig .2.17 In SCA dorsal columns, glial cells do not stain for ferritin but in the ventral 
columns staining appeared as normal as contol 1. 
(A) Ferritin was mainly localized within glial cells (black arrows) in dorsal columns of 
control 1.  A little ferritin was localized in blood vessel walls (bold arrows).  (B) Most 
ferritin was localized within blood vessel walls in the dorsal columns of SCA spinal cord.  
A little ferritin was localized within glial cells of dorsal columns.  (C) and (D) Ferritin 
was mainly localized in glial cells in the ventral columns of control 1 and SCA.  Black 
arrows: glial cells.  Bold arrows: blood vessel walls. Scale =50 µm. 
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Fig.2.18 Ferritin in grey matter of spinal cord. 
(A-C) controls: (A) control 1 (B) control 2 (C) control 3. (D-F) ataxias: (D) SCA (E) 
FRDA 2 (F) FRDA 3.  
(A) Ferritin was abundant in glial cells with less in the blood vessel walls.(B-C) Ferritin 
was found in glial cells and neurons in grey matter of control.  (D) Ferritin was 
abundant within blood vessel walls.  Some ferritin was also found in glial cells.  (E-F) 
Ferritin was found in glial cells and neurons in grey matter of FRDA. 
Black arrows: glial cells.  Bold arrows: blood vessels.  White arrows: neurons. Scale= 
50µm. 
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(black arrows) but also in some “star-shaped” cells (white arrows) and in the glial cells 
(arrowhead, Fig. 2.19G), but no star-shaped cells were seen in the ONC of the FRDA 3.   
As expected, we saw reduced levels of frataxin in the FRDA sections, consistent with the 
diagnosis of FRDA.  The normal appearance of frataxin in the SCA confirmed that this 
SCA of unknown type could not be FRDA. 
2.4.2.1.2. Metallothionein-I+II localization in medulla of ataxias and controls 
Metallothionein (MT)-I+II, copper and zinc binding protein, plays a role in metal 
homeostasis, metal detoxification and scavenges free radicals.  The localization of 
MT-I+II was tested by immunohistochemistry with MT-I+II primary antibody.  The 
negative controls for this antibody showed little background (Fig. 2.20).  
The full scan of FRDA 2 (Fig. 2.21) showed undetectable MT-I+II in the medulla.  
Compared to FRDA 2, the levels of MT-I+II in control 2 (Fig. 2.21) were undetectable.  
Therefore, there was no positive DAB reaction on either FRDA2 or control 2.  
MT-I+II staining was seen in the ONC of control 1 medulla, but the same region in SCA 
(Fig. 2.22) showed no MT staining.  In control 1, the MT-I+II was particularly 
prominent in the dorsal accessory olivary nucleus, inferior olivary nucleus and medial 
accessory olivary nucleus (Fig. 2.23B-D).  The MT-I+II was found within glial cells 
(black arrows) but not neurons in all the three levels of the ONC (white arrows).   
The full scan of MT-I+II localization in control 3 medulla (Fig. 2.24A) showed that 
MT-I+II was localized in the ONC including dorsal accessory olivary nucleus, inferior 
olivary nucleus and medial accessory olivary nucleus (Fig. 2.24B-D).  In all the three 
levels of ONC, MT-I+II was seen within glial cells (black arrows) but not neurons (white 
arrows). 
Because one of the controls did not show MT-I+II reactivity, we also tested various 
disease controls from movement disorders including: Parkinson’s Disease (PD) (Fig. 
2.25A, B), Alzheimer’s Disease (AD) Fig. 2.26A, B) and Progressive Supranuclear Palsy 
(PSP) (Fig. 2.27A,B).  The disease controls showed that MT-I+II was localized to the 
ONC.  MT-I+II was localized in the ONC including dorsal accessory olivary nucleus,  
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Fig.2.19 Frataxin localization within neurons in the inferior olivary nucleus.  
Both normal and disease controls showed high accumulation of frataxin within neurons, 
but only FRDA2 had low levels of frataxin in neurons.  In SCA, more frataxin was 
found within reactive astrocytes as well as neurons. (A-C) normal controls: (A) control 1 
(B) control 2 (C) control 3 (D-F) disease controls: (D) Parkinson’s disease (PD) (E) 
Alzheimer’s Disease (AD) (F) Progressive supranuclear palsy (PSP).  (G) SCA (H) 
FRDA 2.  Black arrows: neurons.  White arrows: reactive astrocytes. Scale=100µm. 
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Fig 2.20 Metallothionein-I+II in medulla compared with negative controls. 
(A) control 1, (B) SCA.  Negative controls: control 1 (C) and SCA (D). Scale=2mm. 
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Fig 2.21 Metallothionein-I+II in FRDA 2 and control 2 medulla.  
There was undetectable MT-I+II in either FRDA 2 and control 2 medulla. Scale=2mm. 
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Fig. 2.22 Full scan of MT-I+II in SCA and control 1 medulla. 
MT-I+II was seen in control 1 but not SCA. Scale=2mm. 
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 Fig.2.23 Metallothionein-I+II was found in glial cells but not neurons of control 1 medulla. 
(A).Metallothionein-I+II was localized within glial cells in the ONC including (B) dorsal 
accessory olivary nucleus, (C) inferior olivary nucleus and (D) medial accessory olivary 
nucleus.  Black arrows: glial cells.  White arrows: neurons. Scale (A) =2mm, Scale 
(B-D) = 50µm. 
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 Fig.2.24 Metallothionein-I+II was found in glial cells but not neurons of control 3 medulla.  
(A).Metallothionein-I+II was localized within glial cells in the ONC including (B) dorsal 
accessory olivary nucleus, (C) inferior olivary nucleus and (D) medial accessory olivary 
nucleus.  Black arrows: glial cells.  White arrows: neurons. Scale (A) =2mm, Scale 
(B-D) = 50µm. 
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Fig.2.25 Metallothionein-I+II was found in glial cells but not neurons of PD medulla. 
(A).Metallothionein-I+II was localized within glial cells in the ONC including (B) dorsal 
accessory olivary nucleus, (C) inferior olivary nucleus and (D) medial accessory olivary 
nucleus.  Black arrows: glial cells.  White arrows: neurons. Scale (A) =2mm, Scale 
(B-D) = 50µm. 
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Fig.2.26 Metallothionein-I+II was found in glial cells but not neurons of AD medulla. 
(A).Metallothionein-I+II was localized within glial cells in the ONC including (B) dorsal 
accessory olivary nucleus, (C) inferior olivary nucleus and (D) medial accessory olivary 
nucleus.  Black arrows: glial cells.  White arrows: neurons. Scale (A) =2mm, Scale 
(B-D) = 50µm. 
 86
  
Fig.2.27 Metallothionein-I+II was found in glial cells but not neurons of PSP medulla. 
(A).Metallothionein-I+II was localized within glial cells in the ONC including (B) dorsal 
accessory olivary nucleus, (C) inferior olivary nucleus and (D) medial accessory olivary 
nucleus.  Black arrows: glial cells.  White arrows: neurons. Scale (A) =2mm, Scale 
(B-D) = 50µm. 
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inferior olivary nucleus and medial accessory olivary nucleus.  In all the three levels of 
ONC, MT-I+II was found within glial cells (black arrows) but not neurons (white 
arrows). 
Taken together, the results of MT-I+II localization in medulla showed a lack of 
detectable MT-I+II in FRDA 3 and the SCA.  MT-I+II was seen within glial cells but 
not neurons in most medulla of the normal controls (except control 3 with long PMI 
29hours) as well as disease controls. 
2.4.2.1.3 GFAP 
GFAP, bio-marker for astrocytes, was used to test whether astrocytes in the ONC had lost 
MT-I+II. 
In the ONC, GFAP was found in both the two controls (Fig. 2.28A-B) and the three 
disease controls (Fig. 2.28C-E).  Reactive astrocytes (black arrows) were only seen in 
the SCA (Fig. 2.28F).  This indicated that there was gliosis in the ONC of SCA.  
FRDA 3 and control 3 showed no GFAP staining at all (data not shown). 
GFAP positive reactive astrocytes were abundant in the ONC of SCA.  But whether the 
loss of MT-I+II in the same region is associated with the reactive gliosis is not tested for 
in this study. 
2.4.2.1.4 Ferritin 
FRDA 3 (Fig. 2.29H) had less ferritin in the ONC than the normal controls.  Ferritin 
was localized within the glial cells (black arrows) in control 1, 2 and 3 (Fig. 2.29A-C).  
The disease controls (Fig. 2.29D-F) had similar levels of ferritin as the three controls, 
which was more than FRDA 3.  Different ferritin localization was found in SCA.  Most 
ferritin was localized in the blood vessel walls (bold arrows); a little ferritin was found 
within the glial cells (black arrows) in the ONC of SCA.  In contrast, no detectable 
ferritin was seen in the blood vessel walls of FRDA 3. 
Due to the interest of discovering the dramatically different localization of ferritin in 
SCA, pictures were taken from other regions including the hypoglossal nucleus (Fig. 
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2.30C), the dorsal nucleus of vagus nerve (Fig. 2.30D) and the inferior and lateral 
vestibular nucleus (Fig. 2.30E).  More ferritin was seen within the blood vessel walls 
(bold arrows) than control 1 ((Fig. 2.31C-E).  The same as in the ONC of control 1 (Fig. 
2.31B-E), some ferritin was localized within the glial cells (black arrows) in the grey 
matter of SCA medulla (Fig. 2.30B-E).  Only part of the ONC (Fig. 2.30B1-2) had 
enhanced level of ferritin in the blood vessel walls (bold arrows).  In ONC, some ferritin 
was accumulated within unusual cells that may be reactive astrocytes that are as large as 
neurons (head arrows).  These unusual cells were not seen in FRDA 3 and the controls. 
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Fig.2.28 GFAP in the inferior olivary nucleus.  
(A) control 1; (B) control 4 (C-E) Disease controls: (C) Parkinson’s disease (PD); (D) 
Alzheimer’s Disease (AD); (E) Progressive supranuclear palsy (PSP); (F) SCA. 
SCA had more GFAP in the inferior olivary nucleus than all controls and disease controls 
indicating gliosis.  Black arrows: positive GFAP.  White arrows: neurons. Scale= 
50µm. 
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Fig.2.29 Ferritin localization in inferior olivary nucleus from normal, disease controls and 
ataxias. 
(Figure legend continues to the next page) 
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(A-C) normal controls: (A) Control 1. (B) control 3 (C) control 4. (D-F) disease controls: 
(D) Parkinson’s disease (PD) (E) Alzheimer’s Disease (AD) (F) Progressive supranuclear 
palsy (PSP) (G-H) ataxias: (G) SCA (H) FRDA 3.  Black arrows: glial cells.  Bold 
arrow: blood vessel. Scale= 50µm. 
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 Fig .2.30 Ferritin localization in SCA medulla.  
Ferritin was localized in both glial cells (black arrows) and blood vessel walls (bold 
arrows) of SCA medulla.  Compared to the normal medulla, SCA had more ferritin in 
blood vessel walls in the grey matter of medulla (including inferior olivary nucleus).  
(A) Full scan of ferritin localization in SCA medulla.  (B1-2) Ferritin localization in 
Area 1.  Inferior olivary nucleus. (C) Ferritin localization in Area 2.  Hypoglossal 
nucleus (D) Ferritin localization in Area 3.  Dorsal nucleus of vagus nerve (E) Ferritin 
localization in Area 4.  Inferior and lateral vestibular nucleus.  Black arrows: glial cells.  
Bold arrows: blood vessels.  White arrows: neurons.  Headless arrows: pathology 
processing neurons. Scale (B-E) = 50µm. 
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Fig.2.31 Ferritin localization in control 1 medulla. 
(Figure legend continues to the next page) 
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Ferrtin was located within glial cells (black arrows) in the grey matter of control medulla. 
(A) Full scan of ferritin localization of control medulla.  (B) Ferritin localization in Area 
1. Inferior olivary nucleus.  (C) Ferritin localization in Area 2. Hypoglossal nucleus (D) 
Ferritin localization in Area 3. Dorsal nucleus of vagus nerve (E) Ferritin localization in 
Area 4. Inferior and lateral vestibular nucleus.  Black arrows: glial cells.  White arrows: 
neurons. Scale (B-E)= 50µm. 
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2.5 Discussion 
2.5.1 Degeneration in dorsal columns of all the three ataxia cases 
In the dorsal columns of FRDAs and SCA, Luxol Fast Blue myelin-stain (section 
2.3.1.1.1) showed fewer myelinated axons than the three controls.  Also, NF 200 axonal 
stain (section 2.3.1.1.2) showed fewer axons than the controls.  The loss of axons and 
demyelination is consistent with the pathology of FRDA and ataxia (Lamarche et al., 
1984).  
NF 200 staining in the dorsal columns of FRDAs and SCA showed a reduced density of 
axons compared to more dense evenly spaced axons in the controls.  There is a large 
area of NF 200 negative material in FRDA and SCA which are not functional axons.  
These materials could be glial scars, which can take the place of damaged normal cells in 
the central nervous system.    
The number of axons in the dorsal columns was much lower in FRDAs and SCA than in 
the controls.  Furthermore, in the ventral columns, the number of axons showed in 
FRDAs (Fig. 2.2-2.3) was lower than in the controls.  While the number of axons in 
ventral columns of SCA looked similar to the controls, they did appear to be fewer 
though (Fig. 2.1).  The quantification in the ventral columns showed the number of 
axons of SCA were 98% fewer than control 1.  This finding indicates that the ventral 
columns in FRDA might also have some degeneration.  
Dorsal columns and ventral columns are two important parts of the white matter in the 
spinal cord.  The normal dorsal columns, filled with myelinated nerve fibers, are related 
to kinaesthesia and discriminative touch (Lin et al., 2003).  Injury to this area will result 
in reduction or loss of the vibratory sense, the positional sense and touch and weight 
perception (Lin et al., 2003).      
We expected to see NF 200 stain in both neurons and axons.  But the result of its 
staining in the grey matter of the spinal cord was variable in the neurons (Fig. 2.7).  
Only neurons of control 3 and FRDA 2 were positive, while control 1 and SCA were 
negative.  Since the antibody worked as expected in some tissues and fresh antibody 
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was prepared for each set of slides, the failure of NF 200 to bind may indicate that the 
tissue no longer had neurofilament 200 antibody-binding sites.  Several things can result 
in the failure of antibody to bind to tissue.  Long PMI may have induced protein 
degradation.  When retrieving tissues out of body, perhaps the extraction time was too 
long or the temperature was too high to protect the protein native structure.   The 
concentration of storing solution contains 10% formalin which is higher than the normal 
2% storing solution for the tissues used for immunohistochemistry (Grethen, 1967).  
The prolonged storage and the high temperature conditions during paraffin embedding 
might not have preserved tissue antigens well.  
In FRDA 3, the tissue seems to be degraded with the loss of neurons.  This might be 
because FRDA 3 has a relatively long PMI or other unknown damages which happened 
to the sample during fixing, handling or storage. 
Except for the variable neuron staining, the NF 200 is an excellent marker to detect axons.  
In the dorsal horns a smaller number of axons were seen in both FRDAs and SCA than 
the controls.  This loss of axons in FRDAs and SCA suggests that the dorsal horns of 
spinal cord might be affected.  Dorsal horns receive information from sensory neurons, 
and their cell bodies are located in the dorsal root ganglion.  Since the neurons in the 
dorsal root ganglia are severely affected in FRDA (Pandolfo, 2008), it is not surprising 
that the dorsal horns also degenerate during the progression of FRDA.  Therefore, our 
findings on loss of axons in the dorsal horns of FRDAs are consistent with FRDA 
pathology. 
2.5.2 Gliosis is seen in the dorsal horns and dorsal columns 
There was gliosis of astrocytes in dorsal horns and dorsal columns of both FRDA 2 and 
SCA spinal cord (section 2.3.1.1.2).  This finding confirmed axonal degeneration in 
dorsal horns and dorsal columns of FRDAs and SCA.  Generally when axons are 
damaged by CNS injury or disease, astrocytes take the place of the original axons and 
produce glial scars instead.  In our findings, the loss of axons and gain of astrocytes in 
dorsal horns and dorsal columns can be explained by this principle.  In addition, reactive 
astrocytosis were also seen in the ONC of medulla in SCA (section 2.3.2.1.3).  This 
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suggests that not only the spinal cord but also the medulla of ataxias might be affected.  
Although the functions of reactive astrocytes are not well understood, their frequent 
appearance after CNS tissue damage or degeneration might give some hints.  The 
reactive astrocytes might correlate with some harmful effects such as inhibiting axonal 
regeneration and releasing cytotoxin, or play roles in protecting neurons and 
oligodendrocytes (Sofroniew, 2005).  Therefore, our results suggest that the presence of 
reactive astrocytes at least indicate the tissues are in the process of being damaged.  We 
cannot distinguish whether these reactive astrocytes function as a regeneration inhibitor 
or cell protector.  
2.5.3 Frataxin deficiency in FRDA and abnormal frataxin distribution in the 
spinocerebellar ataxia 
In the grey matter of FRDA 3 (Fig. 2.12 F) some medium sized, spindle-shaped cells 
were labelled by frataxin.  This staining may be an artifact because the length is about 
the size of a neuron but the shape is far away from normal neurons. 
Due to the abnormal long GAA repeats in the frataxin gene, the level of frataxin protein 
in FRDA should be lower than normal (Pandolfo, 2008).  In our results (see section 
2.3.1.2.1 and 2.3.2.1.1), the level and distribution of frataxin in all controls and disease 
controls remain the same.  As we expected, frataxin in FRDAs was undetectable in the 
axons of white matter and low in the neurons of both the spinal cord and the medulla.  
Although there was loss of axons in dorsal columns, frataxin was seen in the remaining 
axons of SCA.  This proves that the SCA is not the same as FRDA, which is caused by 
frataxin deficiency.   
Besides neurons and axons, frataxin was found not only within glial cells in the normal 
controls but also in SCA.  In the ventral columns, star-shaped glial cells were found 
between axons had highly elevated frataxin.  These special cells look like reactive 
astrocytes cells because of their star like shapes.  But we did not observe the same 
morphology from the GFAP immunochemistry.  Further co-localization experiments 
(GFAP + frataxin) are needed to be done to determine whether they are astrocytes or not.  
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In ONC of SCA medulla (Fig. 2.19G), the distribution of frataxin was quite different 
from controls and even FRDA.  There was a large amount of frataxin located in neurons 
but also in some “star-shaped” cells and in glial cells.  This was not seen in the normal 
controls and the disease controls.  
2.5.4 MT is abnormal in degenerating tissues from FRDA and SCA 
In previous work done in the laboratory (Popescu, submitted), it was found that there was 
abnormal metal distribution in both SCA and also in FRDA (Popescu et al. 2009).  
FRDA 2 and control 2 of medulla did not show any positive MT-I+II (Fig. 2.21).  This 
might be because both of them have relatively long PMI 13-37 hours and 29 hours, 
respectively, and MT antigenicity may have been lost.   Antigenicity might also have 
been lost during fixing, handling or storage especially in FRDA 3 because its sections 
always seem to be degraded or vacuolated.  
The MT in the spinal cord of control 2 (Fig. 2.14) showed positive but diffuse staining 
that was more intense in the grey matter than in control 1.   In contrast, control 1 
showed what appeared to be MT staining in the cells of the grey matter and in the dorsal 
horns.  In both control 1 and control 2 MT staining can be observed, only the pattern 
was a bit different.  The diffuse staining and the long PMI (19 hours) of this sample 
suggest that the MT protein in control 2 has degraded or diffused.  FRDA2 showed no 
staining for MT but in this case the long PMI (21 hours) could also enhance the 
degradation of MT protein.  Since only GFPA staining showed distinct cells in the grey 
matter of FRDA2, the PMI may have been too long for good grey matter preservation.  
As mentioned in the Introduction, MT-I and II function as neuron protectants by binding 
copper and zinc but can also detoxify heavy metals found in the environment.  By 
binding metals, MT can prevent the formation of free radicals (Penkowa, 2006).  ROS 
and metals can induce MT expression (West et al., 2008).  In many CNS diseases such 
as Parkinson’s Disease and Alzheimer’s Disease, MT expression was found to be 
increased (Penkowa, 2006).  We were expecting that the MT level would be elevated in 
FRDA because it is elevated in other instances of oxidative stress and iron accumulation 
(West et al., 2008).  But we found that the level of MT was undetectable in spinal cord 
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grey matter and dorsal horn in both FRDA and SCA.  In the degradation process of MT, 
metal bound state plays an important role.  Metal-MTs have far longer half-lives than 
apo-MT (Miles et al., 2000).  It suggests that the bound metals can increase the stability 
of MTs and protect proteins from degradation.  If metals are deficient in cells, the MTs 
could be degraded more easily and rapidly, but also MT synthesis would not be triggered.  
Our results showed undetectable MT in FRDA and SCA and we hypothesize that this is 
linked to the low levels of copper and zinc seen by spectroscopic mapping (Popescu et al. 
2009).  
Previous results in our lab using a novel synchrotron rapid metal scanning found that 
copper was decreased in the areas of degeneration (Popescu et al. 2009).  Metals 
(copper, zinc and iron) in the spinal cord of the SCA were reduced in dorsal columns 
where degeneration is severe, and elevated in ventral columns where degeneration is not 
so severe.  In this study, MTs were elevated in the dorsal horns and grey matter of 
controls but undetectable in FRDA and SCA.  In controls, copper but not zinc was 
found where the MT was localized in the grey matter of the spinal cord and this suggests 
that here MT is binding copper.  In contrast in the control medulla the region with 
highest copper is not where we find MT.  The highest copper is in the white matter 
surrounding the grey matter of the ONC while the highest MT is within glia within the 
ONC.  The presence of high copper in the olive is a new and unexpected finding.  
Therefore it is not known what the copper is bound to but since we found no MT1+II 
reactivity, the most likely copper binding proteins are MT III (Hidalgo et al., 2001), Cu, 
Zn-SOD (Culotta et al., 2006) or a copper chaperone such as CCS (copper chaperone for 
superoxide dismutase) (Harvey & McArdle, 2008).  In SCA, copper was absent from the 
entire olive (Popescu, 2008).  We found that MT was also completely absent from the 
grey matter of the ONC.  Since the degeneration of the olive is not extensive, the 
absence of MT may be significant in the pathology of SCA but more work is required to 
determine what the role of MT and copper might be in this disease.  
The results have clearly shown decreased MTs in the FRDA and SCA.  This hints that a 
certain type of cell or at least MTs in this type of cell is missing.  In order to find out 
what type of cell it is, a co-localization experiment needs to be done, preferably using 
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unfixed frozen sections with GFAP (marker of astrocytes) and MT since MT is mainly 
localized in astrocytes.    
2.5.5 Reduced cytosolic ferritin in FRDA 
We saw a decreased level of ferritin in the FRDAs in the dorsal columns (Fig. 2.15-2.16), 
ventral columns (Fig. 2.15-16), grey matter of the spinal cord (Fig. 2.18) and ONC in 
medulla (Fig. 2.29).  Therefore, it is clear that ferritin was decreased in FRDAs.  
Ferritin functions as intracellular iron storage while the expression of ferritin is regulated 
by cellular iron levels.  When iron level is low, iron regulatory protein (IRP) binds to the 
iron responsive element (IRE) in the mRNA of ferritin (Aisen et al., 2001).  This 
binding blocks translation of ferritin.  Therefore, the decreased level of ferritin in the 
FRDAs suggests that there is a low level of cellular iron.  Furthermore, the overload of 
iron within mitochondria has been identified in FRDA patients.  The literature supports 
the idea that in FRDA there is an iron overload in mitochondria and this induces an iron 
deficiency in the cytosol.  It has been shown that mitochondrial ferritin increased and 
took up iron within mitochondria of FRDA fibroblasts (Popescu et al., 2007) but it is not 
known if the same thing occurs in neural tissue.  If mitochondrial ferritin does increase 
in neural tissue we may not see this because the amount of mitochondrial ferritin is very 
small.  The antibody used was the same one used previously in our lab to detect 
mitochondrial ferritin but within tissue slices permeabilization of mitochondria may not 
be adequate to detect this type of ferritin.  
Ferritin is normally expressed in neurons, microglia and oligodendrocytes (Ill et al., 
2006).  We found a very distinct distribution of ferritin in the SCA case.  Some ferritin 
was seen in neurons and glial cells but an unusual finding was that ferritin was found 
abundantly in blood vessel walls; this was especially evident in the areas where 
pathological degeneration happened such as the dorsal columns of the spinal cord, the 
grey matter of the spinal cord and the ONC of the medulla.  This suggests that there is 
some relationship between pathological degeneration and distribution of ferritin in the 
SCA.  Ferritin, iron storage protein, plays an important role in protecting endothelium 
cells from oxidative damage (Balla et al., 1992).  Ferritin can inhibit oxidant-induced 
(such as reactive ferrous iron) cytolysis through sequestrating iron (Balla et al., 2007). In 
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vitro, in the presence of oxidant, apoferritin was taken up into cultured endothelial cells 
in a dose dependent manner.  The increased concentration of intracellular apoferritin 
was associated with the decreased cyto-toxicity (Balla et al., 1992).  This suggests that 
endothelium cells are protected from oxidant damage through ferritin.  Therefore the 
elevated ferritin in the blood vessel walls of SCA may be suggestive of oxidative stress 
challenge in its endothelial cells.  
2.6 Summary 
Demyelination and loss of axons were found in the dorsal columns of spinal cord in 
FRDAs and SCA, which is consistent with the established pathology of FRDA.  Gliosis 
of astrocytes is seen in the dorsal horns and dorsal columns of FRDA and SCA.  Not 
only the spinal cord but also the medulla of ataxias was affected by reactive astrocytes.  
The presence of reactive astrocytes indicates tissue atrophy.  But the function of these 
reactive astrocytes whether as a regeneration inhibitor or cell protector is not known, and 
future experiments to determine this needed to be done. 
The metal binding proteins in FRDA and SCA tested in this project were distributed 
abnormally compared to controls.  As expected, the frataxin decreased only in FRDA 
but not in the SCA, the normal controls or the diseases controls.  No detectable MT in 
the FRDA and the SCA of the spinal cord and the medulla was seen.  It can be 
suggested that this might be linked with the low levels of copper and zinc, as seen by 
spectroscopy.  
A certain type of cell or at least MTs in this type of cell is missing.  In order to find out 
what type of cell it is, a co-localization experiment needs to be done.  It is most likely to 
try GFAP (marker of astrocytes) co-localization with MT, since MT is mainly localized 
in astrocytes.  Since the degeneration of the olive is not extensive, the absence of MT 
may be significant in the pathology of SCA but more work is required to determine what 
the role of MT and copper might be in this disease. 
We saw decreased level of ferritin in the FRDAs in the dorsal columns, ventral columns, 
grey matter of the spinal cord and the ONC in the medulla.  This suggests that there is a 
low level of cellular iron in FRDA. 
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In summary, here we have demonstrated an abnormal pattern of metal binding proteins in 
FRDA including decreased frataxin, undetectable MTs and decreased ferritin.  
All in all, it is the first time to show that rapid growth rate seems to be characteristic of 
FRDA fibroblasts.  The rapid growth rate of FRDA fibroblasts might contribute to the 
elevated oxidative stress level of the disease.  I am first time to show that FRDA and 
SCA exhibit abnormal metalloproteins distribution in spinal cord and medulla.  
Therefore, in addition to iron related proteins, other metalloproteins might be involved in 
the pathology of FRDA.  
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APPENDIX 
Cresyl Violet Solution (Filter before use): 
             Amount            Final concentration 
Violet cresyl acetate             0.1g                   0.13% 
Distilled water                  75mL 
 
Luxol Fast Blue (Filter before use): 
                      Amount            Final concentration 
Solvent blue 38-practical grade      0.1g                    0.1% 
95% ethanol                    100mL 
Acetic acid                      0.5mL 
 
Medium for cell culture: 
                       Amount            Final concentration 
Minimum Essential Medium (MEM)     100mL 
1M sodium bicarbonate                2.62mL                23.4mM 
CO2                                5 minutes  
                               (adjust PH to 7.4-7.6) 
Fetal bovine serum          11mL                10% 
Antibiotic and antimycotic                1mL                100units/mL 
